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General introduction
Being born is a great challenge. In utero, the fetus is totally depended on the mother 
through the placenta and umbilical cord, and must establish itself as a dependent air 
breathing individual. This transition can be complicated by hypoxia and acidosis. 
This makes intrapartum surveillance a prime task for midwives and obstetricians. 
The goal is to identify the fetus that will benefit from timely intervention before 
substantial damage has occurred.
For this purpose, cardiotocography (CTG) - a simultaneous recording of the fetal 
heart rate and the contractions of the uterus -, was introduced into obstetric practice 
during the 1970s and 1980s and is still a key component of modern obstetrics. The 
introduction was made on the assumption that CTG would help to reduce cerebral 
palsy caused by intra partum hypoxia/acidosis. Forty years have since passed and 
there has not been any evidence to show an improvement in cerebral palsy (Figure 1). 
What has changed dramatically though, is the cesarean section (CS) rate, which has 
risen four- to fivefold. The sad conclusion is that this has cost us more in terms of 
maternal morbidity and mortality than it has benefited babies (1).
Figure 1. Cerebral palsy prevalence (black bars) and the cesarean section rate 
(dark gray bars) in developed countries.  From: Clark SL, Hankins GD. Temporal and 
demographic trends in cerebral palsy--fact and fiction. American Journal of Obstetrics 
and Gynecology. 2003.
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The main reason for this is the  high inter-and intra observer variation of CTG; whereas 
a normal CTG tracing almost entirelyexcludes hypoxia/acidosis, a non-reassuring or 
abnormal tracing has a high false positive rate of at least 50% for this outcome (2, 3). 
Lack of universally accepted guidelines and poor inter observer agreement on 
tracing interpretation have probably contributed to the limited effectiveness of CTG 
monitoring. The International Federation of Gynecology and Obstetrics (FIGO) 
published its first guidelines on CTG interpretation in 1987 and established the 
only international consensus guideline available to date. Since then, several national 
scientific organizations have published intra partum fetal monitoring guidelines 
including; the American College of Obstetricians and Gynecologists (ACOG), the 
National Institute of Child Health and Human Development (NICHHD), the Royal 
College of Obstetricians and Gynaecologists (RCOG), and the National Institute of 
Clinical Excellence (NICE). These guidelines differ substantially, not only in the 
definition of individual CTG features but also in the criteria used for overall tracing 
classification (4). These differences have a profound effect on the inter-observer 
agreement and reliability, on the way clinicians interpret CTG tracings, as well as on 
the predictive value of CTG classifications for fetal acidemia (5).
Consensus guidelines are usually developed by experts, but the majority of healthcare 
professionals that need to apply them have other areas of main professional focus. It 
is therefore likely that many of the concepts contained in guidelines are only partly 
assimilated and are prone to be easily forgotten. In order to increase assimilation 
and the retention of knowledge it is better to keep guidelines as simple as possible 
and to establish a clear association between the different tracing classifications 
and subsequent clinical management, for example: normal tracings – no actions 
required; suspicious tracings – continue monitoring, perform additional testing, or 
minor interventions (such as reducing maternal temperature); pathological tracings 
– immediate intervention to revert the cause of fetal hypoxia or rapid delivery if 
reversal is not foreseen.
In the Netherlands, the national guideline on fetal monitoring by the Dutch Society 
of Obstetricians and Gynecologists (NVOG) provides such an association between 
CTG classification and subsequent clinical management (6). Besides this national 
guideline, various local protocols exist. The NVOG guideline is frequently used 
(58%), sometimes in combination with a local guideline (26%). In 36% of hospitals, 
only local protocols are used (7). It is not known whether and how the variation in 
guidelines influences the variation in clinical practice with regards to the diagnosis 
and management of fetal distress during labor. What is known is that fetal monitoring 
with CTG only results in variable, but inappropriately high operative delivery rates. 
heinis-layout.indd   12 08/02/2018   15:19
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Over the last four decades, many methods have been proposed to reduce this high rate 
with the use of supplementary tests to confirm or exclude the diagnosis of hypoxia/
acidosis in case of CTG abnormalities. The two best known and accepted ones are 
fetal blood sampling (FBS) and ST analysis of the fetal electrocardiogram (STAN).
The technique of FBS was first described by Erich Saling in Berlin in 1962 (Figure 2) 
(8). This extract from his original paper in 1966 outlines the FBS technique; “The 
presenting part of the foetus is visualized, either with the help of a conical endoscope or, 
if the cervix is sufficiently dilated, with a speculum. After making the skin hyperaemic 
by freezing with ethylchloride spray, it is smeared with a layer of paraffin oil so that the 
blood will collect in a drop. A stab incision is made. The blood that collects is sucked into 
a heparinized capillary tube, and its pH measured. The Astrup equipment is suitable for 
pH measurement, and allows also the Pco2, bicarbonate, and base excess to be measured. 
An acidosis can thus be characterized as either metabolic (lowered bicarbonate and base-
excess), or respiratory (raised Pco2)”.
Figure 2. Foetal blood sampling. The presenting part has been pricked, and a drop of 
blood is about to be sucked into a heparinized tube, held in special forceps.
Saling chose a pH < 7.20 as a cut-off value to recommend intervention. Based on 
a series of 306 fetuses, which were all born in a vigorous state, pH normal ranges 
were calculated by adding and subtracting two standard deviations from the mean 
(Figure 3) (8). Almost 20 years later, Saling reported on the number of fetal deaths 
over a 30-year period among 50 000 deliveries during the change in fetal monitoring 
heinis-layout.indd   13 08/02/2018   15:19
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from auscultation alone (1955–1960) to auscultation in combination with FBS 
(1961–1967) to CTG and FBS (1968–1979). Intra partum deaths fell in these three 
time periods from 0.8 to 0.32%, and then to 0.15%. He credited FBS as the main 
reason for this decline (9). FBS was introduced as an additional clinical test in many 
obstetric units during the 1970s and 1980s and has remained in daily use.
Figure 3. Cut-off values for pH in the different stages of labor and post-partum in the 
umbilical vessels from the original paper by Saling in 1962.
There are some practical problems surrounding FBS. The analysis of pH is 
complicated; a relatively large amount of blood (30-50 µl) is needed, and sampling 
failure rates are high (up to 20%) (10, 11). In addition, pH does not discriminate 
between respiratory and metabolic acidemia, the latter being associated with poor 
neonatal outcome (12). Saling and others have therefore suggested to add base deficit 
(BD) to FBS, as occurs in testing umbilical cord blood. However, BD is a calculated 
value from pH and pCO2, and algorithms for its calculation are intended for adults 
and differ between blood gas analyzers. Moreover, no cut-off values for intervention 
are available. This makes the role of BD in FBS questionable. In contrast, lactate 
is the measured end product of anaerobe glycolysis and therefore a good marker 
of metabolic acidosis. Point of Care (POC) lactate testing devices need only a tiny 
amount of blood, deliver fast results, and have a high success rate, which is very 
convenient in FBS (13-15). In a large randomized controlled trial of 3000 women, 
lactate was compared with pH in FBS, no significant differences were found in terms 
of mode of delivery or neonatal outcome (16). Therefore, POC testing of blood 
lactate can be used as an alternative for pH analysis in FBS. There is no established 
“gold standard” for lactate determinations and therefore the calibration alignment 
of POC lactate devices can differ. As such comparisons between different devices 
have usually shown excellent correlations but often with differences in absolute 
values. Therefore, reported lactate concentrations should be regarded as a figure on a 
heinis-layout.indd   14 08/02/2018   15:19
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relative scale rather than an exact measurement of a concentration. For POC lactate 
measurements, several devices are available. Lactate Pro™ (LP) (Arkray, Kyoto, Japan) 
is an electrochemical test strip device which requires a blood sample of 5 µL, with 
result available after 60 seconds at a low failure rate (1-2%). Based on observational 
data, cut-off values for lactate in FBS measured with LP were suggested (17). These 
cut-off values were tested in the above mentioned RCT, where lactate was found to be 
at least as good as pH in the management of non-reassuring CTG, with significantly 
less sampling/analysis failure rates (14). Unfortunately, the production of the LP 
meter is discontinued. Another POC lactate device is Statstrip Lactate (SSL) (Nova 
Biomedical). This device utilizes 0.7 µL of blood and results are available in 13 sec.
Another example of an adjunctive test to CTG is STAN. This technique detects 
changes in the ST segment of the fetal ECG (ST events) during labor, which are 
related to fetal hypoxia. The occurrence of these ST events is interpreted together 
with CTG, according to the STAN clinical guidelines. Meta-analysis comparing 
STAN to CTG with or without FBS has confirmed a lower rate of metabolic acidosis 
(RR 0.64, 95% CI 0.46-0.88), a reduction in the rate of FBS (RR 0.59, 95% CI 
0.45-0.79) and a reduction in the overall rate of assisted vaginal delivery (RR 0.92, 
95% CI 0.86-0.99). There was no reduction in the rate of operative delivery for fetal 
distress, perinatal death, seizures and encephalopathy (18). Two trials have shown 
that STAN is cost-effective when compared to CTG used in conjunction with FBS 
(19, 20). It is unclear if the use of STAN makes FBS redundant or not. An important 
issue in intrapartum fetal monitoring, is avoiding the occurrence of false-negative 
test results leading to the birth of an infant with adverse outcome. There have been 
reports of false negative results associated with the use of the STAN
 
technique (21-
23).
 
Based on these reports, the existing STAN clinical guidelines were updated in 
January 2007, to include recommendations for situations in which additional fetal 
information is required, such as performing an FBS test (24).
In the Netherlands, a large practice variation exists in fetal surveillance during labor. 
Although all Dutch labor wards use CTG, in 23% (N = 20) of the hospitals STAN 
is used to monitor fetal well-being. In all but one hospital (98%), FBS facilities are 
available, but the frequency of FBS use varies between 3-15% of deliveries (7, 25). It 
is suggested that this is mainly due to the variation in the indication to perform FBS. 
Evidence based guidelines on when to perform FBS are lacking. Furthermore, there 
is ongoing discussion on whether to use pH or lactate as a marker in FBS. As there is 
still uncertainty about the scalp lactate level at which to initiate intervention during 
labor most Dutch hospitals continue to test pH in FBS.
heinis-layout.indd   15 08/02/2018   15:19
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The ideal method for intra partum fetal monitoring would be simple, noninvasive, 
and applicable to all women in labor, irrespective of gestational age. Furthermore, 
the method should ideally satisfy three criteria. Firstly, the method should give an 
early warning (when the baby is only pre-acidemic), to provide time for the clinician 
to deliver the baby without putting the mother at unnecessary risk. Secondly, system 
feedback should be clear (“do we have a problem? yes or no”) and easy to follow 
guidelines should be available. Thirdly, the test should be able to identify the non-
hypoxic fetuses so unnecessary intervention can be avoided. Neither FBS, nor STAN 
fulfill all of these criteria, but their integrated use could be the way to move forward.
In this thesis, we wish to elaborate further on these challenges with the following 
aims:
• To study the inter- and intra-observer agreement of non-reassuring CTG 
patterns and subsequent clinical management (Chapter 2).
• To investigate to what extent the fetal scalp blood lactate concentration during 
labor correlates with fetal scalp pH, base deficit, and metabolic acidosis at birth, 
and to identify which lactate cut-off values can serve as indicators for either 
reassurance or immediate intervention (Chapter 3).
• To study the performance of two POC lactate meters when used for scalp blood 
lactate analysis during labor (Chapter 4).
• To evaluate the Statstrip Lactate for its use in FBS in the clinical setting (Chapter 5).
• To investigate the effects of the implementation of an expanded fetal monitoring 
protocol consisting of STAN and FBS with combined lactate and pH testing, 
on FBS success, delivery intervention rates and perinatal outcome (Chapter 6).
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INTER- AND INTRA-OBSERVER AGREEMENT OF 
NON-REASSURING CARDIOTOCOGRAPHY ANALYSIS 
AND SUBSEQUENT CLINICAL MANAGEMENT
Sarah Rhöse, Ayesha MF Heinis, Frank Vandenbussche, 
Joris van Drongelen, Jeroen van Dillen
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Abstract
Objective: To quantify inter- and intra-observer agreement of non-reassuring 
intrapartum cardiotocography (CTG) patterns and subsequent clinical 
management.
Design: Methodological study.
Setting: University Medical Center.
Population: CTG patterns of 97 women beyond 37 weeks of gestation with 
a singleton fetus in vertex position in first stage of labor in whom fetal blood 
sampling (FBS) had been performed.
Methods: Nine observers assessed CTG patterns, which were formerly 
clinically classified as non-reassuring and indicative for FBS, according to 
the guidelines of the International Federation of Gynecology and Obstetrics 
modified for ST analysis. They also proposed clinical management strategies 
without and with insight into clinical parameters. Weighted kappa values (Kw) 
and proportions of agreement (Pa) were calculated.
Main Outcome Measures:  Agreement on CTG classification and clinical 
management.
Results: Inter-observer agreement on CTG classification and on clinical 
management were poor for most observer categories (Kw range 0.31 – 0.50 and 
0.20 – 0.45, respectively). Observers agreed best on abnormal CTG patterns 
(Pa range 0.28 – 0.36) and on the clinical management option ‘continue 
monitoring’ (Pa range 0.32 – 0.40). Intra-observer agreement was fair to good 
for most observers (Kw 0.33 – 0.70). Insight into clinical parameters resulted 
in similar inter- and intra-observer agreement.
Conclusions: There was poor inter-observer agreement and fair to good intra-
observer agreement on classification and clinical management of intrapartum 
CTG patterns, which had been classified as non-reassuring and indicative for 
FBS during birth.
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Introduction
CTG is a technique used to monitor intrapartum fetal condition. It is a continuous 
simultaneous record of the fetal heart rate and of the presence of uterine activity (1). 
To classify a CTG pattern several classification systems exist, of which the FIGO/
STAN guidelines have probably reached broadest consensus (2). One of the main 
disadvantages of the CTG is that there is substantial variation in interpreting CTG 
patterns. Previous research has shown that inter- and intra-observer agreement of 
CTG classification is often poor (3-6). Also, the specificity of a CTG is low, i.e. 
many false-positive test results for poor neonatal outcome (7). As a consequence, 
unnecessary obstetric interventions for suspected fetal distress are performed (1, 
7-9). In an attempt to reduce these unnecessary interventions, FBS can be used as a 
diagnostic test to gain additional information on fetal condition (10). Nevertheless, 
FBS is an invasive, cumbersome procedure with failure rates up to 20 % (8), and it is 
only assumed that FBS reduces the cesarean section rate. Therefore, its use should be 
balanced in an effort to keep both cesarean section rate and FBS rate at a reasonable 
level.
Various observations suggest considerable variation in the indication to perform 
FBS. Firstly, FBS use varies between countries, hospitals and care workers. In the 
Netherlands FBS is performed in 3 to 15 % of deliveries (11), while these percentages 
are different in other countries (12-14). Secondly, evidence based guidelines on when 
to perform FBS are lacking. (15, 16) Also the impression exists that FBS is performed 
on more liberal indications than described in these guidelines, i.e. for reassurance on 
fetal condition before active pushing is started. Hence, there is significant variation 
in the use of FBS, which could be explained by variation in the indication to perform 
FBS.
The objectives of this study were to quantify variation (i.e. inter- and intra-observer 
agreement) in (i) the classification of intrapartum CTG patterns prior to FBS, 
according to the FIGO/STAN guidelines (17), and (ii) management based on this 
classification. The impact of insight into clinical parameters and also of the observers’ 
level of experience was analyzed. In addition, the relation between fetal scalp pH and 
CTG category was evaluated.
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Material and methods
We performed a methodological study at the Radboud University Medical Center, 
which is a tertiary referral hospital with approximately 1500 deliveries a year. In  the 
Netherlands, independent primary care midwives provide care to low risk women. 
If complications or risk factors occur during pregnancy, labor, or after birth, women 
are referred to secondary or tertiary care. After referral, care may be provided by 
clinical midwives or obstetric registrars but always under final responsibility of an 
obstetrician. Fetal condition during labor is monitored with continuous CTG and 
FBS is performed in 11 % of deliveries (18). The Research Ethics Committee at the 
Radboud University Nijmegen Medical Center approved the study (2012/080).
We selected all women who delivered between February 2010 and March 2011 and 
in whom FBS was performed based on a non-reassuring CTG during the first stage 
of labor. Women were included if they complied to the following inclusion criteria: 
singleton fetus in vertex position, gestational age of 37 weeks or over, and optimal 
CTG registration 60 minutes prior to FBS.
Nine observers were asked to participate in the study. They were divided into three 
groups according to their specialty level and level of experience in obstetrics. Group 
A contained four obstetricians with at least one year of experience as obstetrician. 
Group B contained three registrars gynecology in their second or third educational 
year (full educational period is six years with obstetrics incorporated in each year). 
Group C contained two clinical midwives with two to three years of
clinical experience. All observers use fetal monitoring with CTG regularly in clinical 
practice. They received training as standard part of their education. Knowledge about 
CTG interpretation is exchanged in the daily morning protocol were CTG patterns 
are discussed with attending midwives, registrars and obstetricians.
For each case, we extracted CTG patterns from the obstetric database of the Radboud 
University Medical Center. We identified the 60-minute CTG pattern prior to FBS. 
If fetal blood was sampled more than once, the CTG pattern prior to the first sample 
was used. We also extracted clinical parameters, including general information 
(maternal age, obstetric history and risk factors in the current pregnancy), parameters 
that influence progression of labor (parity, cervical dilatation, augmentation of 
labor) and parameters that influence fetal condition (gestational age, the presence 
of meconium stained amniotic fluid, maternal body temperature and estimated fetal 
weight).
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The nine observers were asked to assess the CTG patterns twice with an interval 
of at least one month: T0 and T1. To assess the CTG patterns, a web-based tool 
was developed which provided the observers with CTG patterns and corresponding 
clinical parameters. This web-based tool did not allow observers to change previous 
answers and presented the cases in random order at T0 and T1. The assessment 
procedure went as follows. First, the observers were shown the anonymized CTG 
pattern (paper speed 2 cm/min, that is commonly used in the Netherlands) and 
were asked to classify it according to the FIGO/STAN guidelines into one of 
four categories: normal, intermediary, abnormal or pre-terminal. At this time 
observers were provided with the information that it concerned a CTG pattern 
from the dilatation phase, of a singleton fetus in vertex position in whom FBS had 
been performed during labor. Secondly, observers were asked to choose a clinical 
management option: (i) continue monitoring with the availability of measures to 
solve the causes of fetal distress by conservative management (for example treating 
hypotension, discontinuing oxytocin infusion, changing maternal position), (ii) 
perform FBS or (iii) immediate delivery (within 15 minutes). Thirdly, observers were 
provided with the corresponding clinical parameters and were then asked again to 
choose a clinical management option.
Statistical analyses
CTG classification and clinical management strategy by different observers were 
used to calculate inter-observer agreement. Intra-observer agreement was calculated 
using observations of the same observer at T0 and T1. SPSS (SPSS for Windows, 
Rel. 18.0.2. 2010. Chicago: SPSS Inc.) and SAS (SAS Institute Inc. 2010. SAS/
GRAPH® 9.2 Reference, Second Edition. Cary, NC: SAS Institute Inc.) were used 
for the data analysis.
For the categorical, ordinal variables ‘CTG classification’ and ‘clinical management’ 
Kw (weighted kappa) was calculated. Pa (proportions of agreement) were calculated 
for each individual CTG category and clinical management option (19). Weighted 
kappa values above 0.75 were considered as excellent agreement, between 0.40 and 
0.75 as fair to good and below 0.40 as poor agreement.
Both Kw and Pa describe the amount of agreement, but in a different way. Kw 
measures agreement beyond agreement expected by chance (20). It measures the 
degree of association between two variables, but not their true agreement (19). Pa 
shows the proportion of cases on which observers agree (20). A limitation of Pa is 
that it does not take into account agreement expected by chance.
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Prior to this study, we performed power analysis. A sample size estimation for 
analyzing agreement (kappa) between two observers was made with α = 0.05 and β 
= 0.2. To investigate the null hypothesis H0: p0 = 0.4 and the alternative hypothesis 
H1: p1 = 0.6, a sample size of 90-100 CTG patterns was estimated (20, 21).
For correlation analysis of CTG classification and scalp pH, we selected those cases in 
which consensus on CTG classification was reached. We defined consensus as CTG 
category inter-observer agreement of more than 75 % of observers (n ≥ 7). Scalp pH 
was considered non-reassuring if pH was below or equal to 7.25 and acidemic if pH 
was below 7.20. For each CTG category the proportion of non-reassuring scalp pH 
was calculated.
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Results
During the study period 1755 women delivered at the Radboud University Medical 
Center. Ninety-seven women met the inclusion criteria. Table 1 summarizes the 
characteristics of the mother and baby pairs. In 15 cases scalp pH was non-reassuring, 
in one case scalp pH was acidotic and in 14 cases scalp pH analysis had failed.
Table 1. Characteristics of 97 mother and baby pairs
Characteristic Number (%) or median (range)
Maternal age in (years) 31 (19 – 43)
Gestational age (days) 281 (263 – 295)
Nulliparous women 78 (80)
Estimated fetal weight 
  SGA1 8 (8)
  LGA2 5 (5)
Cervical dilatation at time of FBS (cm) 7 (3 – 10)
Maternal fever3 16 (16)
Augmentation of labor 71 (73)
Meconium stained amniotic fluid 25 (26)
FBS pH ≤ 7.254 15 (15)
Birthweight (grams) 3440 (2405 – 4618)
  SGA5 11 (11)
  LGA6 9 (9)
1 Small for Gestational Age (SGA): estimated fetal weight below the 10th percentile of the Verburg growth curve 
(25) 2 Large for Gestational Age (LGA): estimated fetal weight above the 90th percentile of the Verburg growth 
curve (25) 3 Maternal temperature ≥ 37.8 ⁰ 4 Fetal blood sampling (FBS) 5 Small for Gestational Age (SGA), i.e. 
below the 10th percentile of the National Perinatal registry curves (26) 6 Large for Gestational Age (LGA) i.e. 
above the 90th percentile of the National Perinatal registry curves (26).
All observers assessed 97 CTG patterns at T0 and T1. Mean assessment time of all 
CTG patterns at T0 was 78 minutes, ranging from 46 to 121 minutes. At T1 mean 
assessment time was 58 minutes, ranging from 29 to 97 minutes. Most CTG patterns 
were classified intermediary or abnormal (Figure 1). The clinical management 
strategy ‘FBS’ was chosen in 23 % of CTG patterns classified as intermediary and in 
72 % of CTG patterns classified as abnormal (Figure 1).
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Figure 1. Clinical management strategy per cardiotocography (CTG) category at T0 (total 
number of CTG patterns was 873 as nine observers each assessed 97 CTG patterns). FBS, 
fetal blood sampling.
At T0, inter-observer agreement on classification of CTG patterns was poor within 
and between most observer categories, except for clinical midwives, whose agreement 
was fair to good (Table 2). Agreement was best for abnormal CTG patterns (Pa 
all observers 0.31). Agreement on clinical management was poor within and 
between most observer categories (Table 3). Registrars and clinical midwives agreed 
moderately. Observers agreed best on the clinical management option ‘continue 
monitoring’.
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At T1, agreement on CTG classification and clinical management strategy was 
slightly lower compared to agreement at T0 within observer categories ‘clinical 
midwives’ and ‘registrars’. Within observer category ‘obstetricians’ and between 
observer categories agreement was similar to agreement at T0. Intra-observer 
agreement on CTG classification and clinical management strategy was fair to good 
for most observers (Table 4). Intra-observer agreement was best on abnormal CTG 
patterns and on the clinical management option ‘continue monitoring’.
At T0, after the observers had received insight into clinical parameters, inter-observer 
agreement was slightly lower within and between most observer categories (Table 3). 
At T1, a similar decrease in inter-observer agreement was seen. The degree to which 
insight into clinical parameters changed intra-observer agreement differed between 
the individual observers (Table 5).
At T0, there was consensus in 43 CTG patterns: 4 normal, 12 intermediary and 25 
abnormal. In these CTG patterns, the proportion of non-reassuring scalp pH was 0 
%, 10 % and 35 %, respectively. At T1, there was consensus in 33 CTG patterns: 4 
normal, 11 intermediary and 18 abnormal. In these CTG patterns the proportion of 
non-reassuring scalp pH was 0 %, 40 % and 23 %, respectively.
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Discussion
We found considerable variation in the classification of CTG patterns. Observers 
agreed poorly with each other and fair to good with themselves on CTG classification 
and clinical management. They achieved highest agreement on abnormal CTG 
patterns and on the clinical management option ‘continue monitoring’.
CTG classification and subsequent clinical management suffer from individual 
interpretation. Literature is not consistent on the degree of agreement in high risk 
deliveries, as inter-observer agreement varies from “poor” to “fair to good” (22-24). 
This inconsistency may be partly dependent upon the used classification system. In 
correspondence to literature (24), we detected poor inter-observer agreement and 
“fair to good” intra-observer agreement when classifying CTG patterns according 
to the FIGO/STAN guidelines.  This implies that, even with strict guidelines, the 
agreement on CTG-classification between observers is poor, although individuals 
appear to score CTG patterns more consistent.
The level of experience and type of profession may influence CTG interpretation. 
Westerhuis et al. showed differences indicative for higher rates of agreement in more 
experienced and recently educated professionals (24). We could not confirm this 
observation, as our study showed that both clinical midwives and registrars agreed 
better than the obstetricians. One may speculate on possible explanations: (i) 
registrars are all trained in the same teaching hospital, while the obstetricians have 
different backgrounds, (ii) clinical midwives and registrars are more “bed-side” than 
obstetricians and have more current experience than obstetricians, (iii) the observer 
category size differed amongst the groups (four obstetricians, three registrars and 
two clinical midwives) which increases the probability that midwives’ fair to good 
agreement was due to chance.
CTG classification is used to identify those fetuses at risk for metabolic acidosis. 
Literature reports that the rate of agreement on clinical management correlates to 
fetal umbilical cord pH at birth (23). In line with literature, we found that CTG 
category correlates with scalp pH if several observers agree about the CTG category. 
However, these results must be interpreted with caution as they are based on a small 
sample. Therefore, it is still unknown whether better agreements are correlated with 
‘true’ interpretations and if better agreement will improve neonatal outcome.
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Some physicians share the opinion that a CTG can only be assessed adequately with 
insight into clinical parameters. We did not find literature that investigated the value 
of additional clinical parameters to CTG interpretation. In our study, the insight 
into clinical parameters did not influence inter-observer agreement. Possibly, the 
degree to which observers included the clinical parameters in their CTG assessment 
was heterogenic. Furthermore, by providing clinical parameters we added more 
variables about which observers could disagree.
Our study provides additional insight in CTG interpretation. However, some 
limitations need to be addressed. Firstly, we only included CTG patterns which were 
formerly clinically classified as indicative for FBS. This may have led to a relatively 
low number of normal and pre-terminal CTG patterns. As a result, sufficient CTG 
patterns were available to say something conclusive about the indication to perform 
FBS with a reasonable total number of CTG patterns (19). Additionally, Westerhuis 
et al. showed good inter-observer agreement on CTG’s classified as normal or (pre)
terminal (24), which makes this category of CTG patterns of less interest. Further, 
all observers were provided with the information it concerned CTG patterns 
formerly diagnosed as non-reassuring and indicative for FBS. This may have 
influenced observers’ assessments, for example by causing them to choose the clinical 
management option ‘FBS’ more often. However, by providing this information 
we ensured all observers assessed the CTG patterns with the same foreknowledge. 
Another limitation is the fact only two midwives participated in our study. In an 
optimal setting, we would have wanted at least three observers in each observer group 
to achieve a narrow enough confidence interval around Pa when using 97 CTG 
patterns. This means the results in the midwives group are more sensitive to observer 
bias and should therefore be interpreted with care. Finally, observers assessed the 
CTG patterns using the FIGO/STAN guidelines, while the CTG patterns stem from 
a period of time in which the FIGO/STAN guidelines were not used at the hospital. 
Probably, the indication to perform FBS had been more liberal at that time.
Our study showed that interpretation, i.e. classification of CTG patterns remains 
difficult even when using the FIGO/STAN guidelines. This has clinical implications 
regarding the use of FBS and fetal monitoring with CTG. Since the positive predictive 
value of FBS is expected to be low if the a priori chance for a fetus suffering from 
acidosis is low, we think the indication to perform FBS should be more strictly 
described to ensure the use of FBS is as efficient as possible. Moreover, physicians 
should be aware of the fact that there is a relatively high chance their colleagues would 
classify a CTG pattern differently or would choose another clinical management 
strategy, underlining the importance of critical discussion between colleagues. There 
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is a need for a stricter and better implemented CTG classification system, which may 
help to increase the rate of agreement on classification and clinical management of 
CTG patterns.
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Abstract
Objective: To study to what extent the fetal scalp blood lactate concentration 
during labor correlates with fetal scalp pH and base deficit, and metabolic 
acidosis at birth, and to suggest lactate cut-off values to serve as indicators for 
either reassurance or immediate intervention.
Design: A retrospective observational study.
Setting: Labor ward at the Radboud University Medical Centre, Nijmegen, 
the Netherlands.
Sample: Fetal scalp and cord blood samples with acid-base and lactate values 
from 486 singleton pregnancies beyond 34 weeks’ gestation.
Methods: The relation between lactate, pH and base deficit (BD) in fetal scalp 
blood was tested by Spearmans’s rho correlation coefficient. Lactate cut-off 
values indicating either reassuring fetal status or immediate intervention were 
estimated using percentile distribution and compared to pH and BD.
Main outcome measures: Metabolic acidosis, defined as umbilical cord artery 
pH below 7.05 and base deficit (BD) calculated for the blood compartment 
above 12 mmol/l.
Results: After 127 (21%) exclusions, 486 cases were available for analysis. 
Fetal lactate values increased with evolving metabolic acidosis. Lactate 
concentration correlated with both pH (r= -0.50, p < 0.01) and BD (r= 0.48, 
p < 0.01). Lactate < 5.4 mmol/l indicated reassuring fetal status, whereas 
lactate ≥ 6.6 mmol/l indicated metabolic acidosis. Fetal lactate correlated 
better with either the absence or presence of metabolic acidosis at birth than 
did fetal pH and BD.
Conclusions: In case of a non-reassuring fetal heart rate, fetal scalp blood 
lactate provides more accurate information on fetal acid-base status than does 
pH and/or BD.
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Introduction
Intra-partum cardiotocography is a useful screening test for hypoxic/acidotic distress 
but requires supplementary tests to avoid unnecessary operative delivery (1). Fetal 
blood sampling (FBS) with pH analysis is used to identify those fetuses with suspected 
distress as actually being acidotic (2). When only pH is used, no differentiation 
is made between respiratory (CO2 accumulation) and metabolic acidosis (lactate 
acidosis). However, poor neonatal outcome is associated with metabolic rather than 
respiratory acidosis (3,4). The base deficit (BD) varies linearly with the degree of 
metabolic acidosis, whereas it is virtually unaffected by respiratory acidosis (5). 
Therefore, full blood gas analysis is considered more informative than pH alone. 
Lactate may be the better indicator of anaerobic metabolism compared to BD. BD 
is calculated from measured pH and pCO2 levels and is therefore sensitive to error, 
whereas lactate is the actual measured end product of anaerobic metabolism.
Analysis of pH is cumbersome in fetal scalp blood, with or without full blood gas 
analysis. The amount of blood needed is relatively large (35–95µL), sampling failure 
rates are high (11–20%), and the logistics of analysis are time-consuming (20–30 
minutes) (6,7). Lactate analysis may be a better alter- native. It requires only a tiny 
amount of blood (0.7–5.0µl), failure rates are low (1.3–2.9%), and results of point-
of- care testing devices are quickly available (13–60 seconds) (7–9).
In the assessment of metabolic acidosis after birth, lactate values in arterial cord 
blood correlate well with pH and BD (10). This suggests that the same may be true 
for fetal scalp lactate concentration as a direct measure of metabolic acidosis during 
labor and delivery. Although fetal scalp lactate has been compared with fetal scalp 
pH, little is known about scalp blood lactate in relation to concomitantly analyzed 
fetal scalp BD (11,12).
This study tested the hypothesis that fetal scalp lactate concentration during labor 
correlates directly with fetal scalp pH and BD and relates to metabolic acidosis at 
birth. To this end, fetal scalp blood data were analyzed concomitantly for lactate, 
pH, and BD, and were correlated both with each other and with metabolic acidosis 
at birth. Fetal scalp blood lactate levels were estimated to serve as indicators for either 
reassurance or the necessity of immediate intervention.
heinis-layout.indd   41 08/02/2018   15:19
42
Chapter 3
Material and methods
The study was conducted with FBS and cord blood data obtained from women 
during labor at the Radboud University Nijmegen Medical Center during a four-year 
period (2004–2007). The Research Ethics Committee at the Radboud University 
Nijmegen Medical Center approved the study (2011/019).
Deliveries were managed by residents or midwives supervised by a gynecologist. 
Cardiotocograms were classified and interpreted according to the guidelines of the 
International Federation of Gynecology and Obstetrics (13). FBS was per- formed 
on indication by the obstetric caregiver in the case of an intermediary or abnormal 
cardiotocography trace. Excluded were women with a pregnancy <34 weeks, multiple 
gestation, or non-vertex presentation, incomplete obstetric record, incomplete set of 
laboratory data on lactate, pH and BD in FBS or cord blood. If FBS was performed 
more than once, only the last sample prior to delivery was included in the analysis.
FBS was carried out by a standard technique (2). After incision of the fetal scalp, 
blood was collected in heparinized plastic capillaries and sent to the laboratory for 
immediate full blood gas and lactate analysis on a blood gas analyzer (Rapidlab 860, 
Siemens Health- care Diagnostics, Deerfield, IL, USA). This required samples ≥35µl. 
Base deficit was calculated for the blood compartment [BD (B)] using the algorithm: 
BD (B)= (1 − 0.014×c tHb)[c HCO3 − −24.8)+(1.43×c tHb+7.7) (pH 7.40)]. Base 
deficit for the blood compartment was used, as it was reported to show a closer 
association with neonatal depression than BD calculated for the extracellular fluid 
compartment (14).
The lactate values were not available for clinical use, but pH, pCO2, and BD were. 
As no intra-partum cut-off values were available for these parameters, only pH was 
used for clinical management. Guidelines for fetal pH were: pH >7.25 normal; 
continue fetal monitoring, 7.21–7.25 pre-acidemia; consider repeat FBS within 30 
minutes, <7.21 acidemia; con- sider immediate delivery. Fetal buffer capacity was 
considered not to be reduced when scalp blood BD was <8.0mmol/l (4,15). A BD 
value ≥10mmol/l, representing the 85th per- centile of the study population, was 
chosen as a marker for the need of immediate intervention.
Metabolic acidosis at birth was systematically evaluated by cord blood sampling 
immediately after delivery from both the umbilical artery and vein, as previously 
reported (16). The umbilical vein results were used to verify correct sampling. Only 
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data from the umbilical artery were used in the analysis, assuming that this was the 
best reflection of fetal condition. Metabolic acidosis at birth was defined as pH<7.05 
and BD>12.0mmol/l in umbilical artery blood (17).
Statistical analysis was performed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA). 
Data are presented as medians with 95 (2.5–97.5) percentile ranges. Data were tested 
non- parametrically by the Mann–Whitney U-test or chi-squared test whenever 
applicable and corrected for multiple testing (Bonferroni correction). Relation 
between two variables was tested using Spearman’s rho correlation coefficient. A 
p-value <0.05 was considered significant. To estimate fetal lactate cut-off values, the 
percentile distribution in the study population was used.
Fetal pH values, divided as normal, pre-acidemia, and acidemia, are used to guide 
clinical management. In analogy with that, we chose the lactate value <75th 
percentile as marker for reassurance and the lactate value >85th percentile as marker 
for the need of immediate intervention. A lactate value between the 75th and 85th 
percentile was considered to reflect the intermediate zone in which repeat FBS 
within 30 minutes might be considered. The ‘predictive’ proper- ties of lactate, pH, 
and BD cut-off values were studied using cross-tabulation. Sensitivity, specificity, 
positive and negative predictive values were calculated.
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Results
During the study period, 5448 women were delivered. FBS was performed in 613 
(11%) women. After 127 (21%) exclusions, 486 cases were available for analysis. 
Median time from sampling to delivery was 54 (33–105) minutes. Lactate, pH, 
BD, and pCO2 values were not normally distributed either in fetal scalp blood or 
in umbilical artery blood after birth. The intra-partum characteristics of the 486 
mother–baby pairs, and lactate, pH, BD, and pCO2 values in fetal scalp blood as 
well as in umbilical artery blood after birth are summarized in Table 1. Seventeen 
(3%) infants had metabolic acidosis at birth.
Table 1. Intra partum characteristics, and fetal scalp and cord blood values for lactate, 
pH, base deficit and pCO2 of 486 mother-baby pairs.
Characteristic Number (%) or Median (range)
Maternal age (years) 32 (28-35)
Nulliparous 354 (73%)
Gestational age (days) 284 (248-297)
Meconium stained amniotic fluid 158 (33%)
FBS Lactate (mmol/l) 3.9 (1.7-9.0)
FBS pH 7.28 (7.08-7.41)
FBS BD (mmol/l) 5.8 (3.0-13.9)
FBS pCO2 (kPa) 6.1 (3.7-9.1)
Operative delivery* 282 (58%)
Five minute Apgar score < 7 15 (3%)
Birthweight (grams) 3442 (2255-4399)
UA Lactate (mmol/l) 6.2 (2.5-11.1)
UA pH 7.19 (6.99-7.32)
UA BD (mmol/l) 8.3 (2.5-15.5)
UA PCO2 (kPa) 7.5 (4.9-10.8)
Metabolic acidosis at birth1 17 (3%)
Data are numbers and percentage of total (%), or medians with 2.5th and 97.5th ranges. *Forceps/ventouse or 
cesarean section. FBS: Fetal blood sample. UA: Umbilical artery. 1pH < 7.05 and base deficit > 12 mmol/l in 
umbilical artery blood.
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Fetal scalp blood lactate correlated significantly with pH and BD (r=−0.50, p<0.001 
and 0.48, p < 0.001, respectively) (Figure 1a, b). Fetal scalp blood samples were 
categorized by pH and BD levels into four groups: group I – pH>7.25 and BD < 
8; group II – pH > 7.25 and BD ≥ 8; group III – pH ≤ 7.25 and BD < 8; group 
IV – pH ≤ 7.25 and BD ≥ 8, indicating nor- mal acid-base status, reduced buffer 
base, hypercapnia in the absence of metabolic acidosis, and metabolic acidosis, 
respectively. Thus categorized, the lactate levels showed a significant increase (p<0.01) 
with progressing metabolic acidosis (Table 2). Median values in groups I and IV 
were concordant for absence or presence of metabolic acidosis, respectively, based on 
lactate, pH, and BD. In groups II and III, the median lactate level appeared to be a 
better indicator of a mild degree of metabolic acidosis compared with BD.
Figure 1a. Relation between lactate and pH (r = -0.50, p < 0.01) in fetal scalp blood.
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Figure 1b. Relation between lactate and BD (r = 0.48, p < 0.01) in fetal scalp blood.
Umbilical artery blood after birth was more acidic than fetal scalp blood, as shown 
by the median values of lactate (6.2 vs. 3.9 mmol/l), pH (7.19 vs. 7.28), and BD 
(8.3 vs. 5.8 mmol/l), and pCO2 was higher (7.5 vs. 6.1 kPa) (Table 1). Umbilical 
artery lactate was significantly related to pH (−0.50, p<0.01) and BD (0.55, p<0.01) 
(Figure 2a, b). Categorized by BD and pH levels, the lactate level in umbilical artery 
blood showed a significant increase (p<0.01) with progressing metabolic acidosis 
(Table 3), except in group III, which contained only three samples, with the highest 
lactate values, and in group IV, which had more severe acidosis. Median values in 
groups I and IV were concordant for absence or presence of metabolic acidosis based 
on lactate, pH, and BD. Group II showed relatively high BD, suggestive of metabolic 
acidosis, as a result of relatively low pCO2. Group III showed relatively low BD, 
suggestive of absence of metabolic acidosis as a result of relatively high pCO2. In 
groups II and III, the median lactate level appeared to be a better indicator of degree 
of metabolic acidosis compared with BD.
heinis-layout.indd   46 08/02/2018   15:19
47
Scalp lactate for intrapartum assessment of fetal metabolic acidosis
C
ha
pt
er
 3
Table 2. Fetal scalp blood lactate, pH, base deficit and pCO2, categorized according to pH 
(7,25) and base deficit (8 mmol/l) thresholds of reassuring fetal acid/base status.
N
Fetal scalp blood
pH > 7.25 pH ≤ 7.25
I
BD < 8
272
II
BD ≥ 8
46
III
BD < 8
69
IV
BD ≥ 8
99
Lactate (mmol/l) 3.3 (1.5 - 6.7) 3.9 (1.4 - 8.5)* 4.5 (2.0 - 8.3)* 6.6 (2.5 - 11.8)*
pH 7.31 (7.26 - 7.43) 7.29 (7.26 -7.38)* 7.24 (7.13-7.25)* 7.18 (7.00 - 7.25)*
BD (mmol/l) 4.3 (0.6 - 7.5) 9.2 (8.0 - 14.5)* 6.0 (3.0 - 7.9)* 10.4 (8.0 - 17.4)*
pCO2 (kPa) 5.9 (3.9 - 7.4) 4.5 (1.9 - 5.7)* 7.3 (6.0 - 9.9)* 6.5 (4.0 - 10.3)*
Data are presented as median values with 2.5th and 97.5th centile ranges; *indicates p < 0.01 compared to group I 
(pH > 7.25 and base deficit < 8 mmol/l).
Table 3. Umbilical artery blood lactate, pH, base deficit and pCO2, categorized according 
to pH (7.05) and base deficit (12 mmol/l) thresholds for metabolic acidosis at birth.
N
Umbilical artery blood
pH ≥ 7.05 pH < 7.05
I
BD ≤ 12
443
II
BD > 12
23
III
BD ≤ 12
3
IV
BD > 12
17
Lactate (mmol/l) 6.0 (2.4-10.4) 8.7 (2.6-14.5)* 10.7 (6.9-10.9) 9.1 (5.8-17.8)*
pH 7.20 (7.08-7.32) 7.09 (7.05-7.20)* 7.04 (6.92-7.04)* 6.97 (6.71-7.04)*
BD (mmol/l) 8.0 (2.5-11.5) 13.4 (12.1-15.5)* 11.1 (10.9-11.3)* 16.4 (13.5-23.2)*
PCO2 (kPa) 7.5 (4.9-9.9) 7.5 (4.8-9.5) 10.8 (10.8-16.1)* 9.8 (6.3-16.9)*
Data are presented as median values and 2.5th and 97.5th centile ranges; *indicates p < 0.01 compared to group I 
(pH ≥ 7.05 and BD ≤ 12 mmol/l).
The 25th percentile for FBS pH was 7.24 and the 75th percentile for BD was 8.4 
mmol/l. These values are close to commonly accepted thresholds for reassuring fetal 
status (pH > 7.25, BD < 8.0mmol/l), for which expectant management is considered 
safe (2,4,15). The 75th percentile for lactate was 5.4 mmol/l and the 75th percentile 
for pCO2 was 6.8kPa. In analogy with the safety margins for pH and BD, for lactate 
we chose the 75th percentile value as the threshold for reassuring fetal status.
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Figure 2a. Relation between lactate and pH (r = -0.50, p < 0.01) in umbilical artery blood.
Figure 2b. Relation between lactate and BD (r = 0.55, p < 0.01) in umbilical artery blood.
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We compared this threshold (5.4 mmol/l) with existing thresholds for fetal scalp 
blood of pH (7.25), BD (8.0 mmol/l), and pH and BD combined, and related 
those to the absence of metabolic acidosis at birth (Table 4). Lactate < 5.4 mmol/l 
had a sensitivity of 77%, a specificity of 88%, a positive predictive value of 99%, 
and a negative predictive value of 12% for reassuring fetal status. Compared to pH, 
BD, and (pH+BD), lactate was a better marker of reassuring fetal status. The 15th 
percentile for pH was 7.20. This value is identical to the commonly accepted threshold 
for immediate intervention (2). The 85th percentile for lactate was 6.6 mmol/l, for 
BD 10.0mmol/l, and for pCO2 7.3 kPa. In analogy with the intervention margin 
for pH, we chose the 85th percentile values for lactate and BD as thresholds for 
immediate intervention.
Table 4. Test characteristics of threshold values for fetal scalp pH (> 7.25), base deficit (< 
8 mmol/l) and lactate (< 5.4 mmol/l) in association with absence of acidosis (pH ≥ 7.05) 
at birth.
Absent acidosis
at birth* Lactate < 5,4 pH > 7.25 BD < 8 pH > 7.25 and BD < 8
Sensitivity (95%CI) 77 (73-81) 67 (62-72) 72 (65-79) 58 (52-64)
Specificity (95%CI) 88 (85-91) 88 (84-92) 76 (69-82) 88 (84-92)
PPV (95%CI) 99 (98-100) 99 (98-100) 99 (97-100) 99 (98-100)
NPV (95%CI) 12 (9-15) 9 (6-12) 9 (5-13) 7 (4-10)
* pH < 7.05 and base deficit > 12 mmol/l in umbilical artery blood. PPV: Positive predictive value, NPV: Negative 
predictive value.
We compared the new fetal scalp thresholds for immediate intervention (lactate 6.6 
mmol/l, BD 10.0 mmol/l) with the existing threshold for fetal scalp blood pH (7.20), 
and related those to the presence of metabolic acidosis at birth (Table 5). Lactate 
≥ 6.6 mmol/l had a sensitivity of 71%, a specificity of 87%, a positive predictive 
value of 16%, and a negative predictive value of 99%. Compared with pH, BD, and 
(pH+BD), lactate was a better marker for the need of immediate intervention.
There were 17 individual cases of metabolic acidosis at birth (umbilical artery pH 
< 7.05 and BD > 12mmol/l). These are shown in Table 6 in order of sampling-to-
delivery interval. There were no acute obstetric complications. Of the 17 cases, 12 
cases were ‘correctly identified’ by lactate by the marker for immediate intervention 
(≥ 6.6 mmol/l), seven by pH (≤7.20), and nine by BD (≥ 10 mmol/l). Five cases 
were ‘correctly identified’ by all immediate intervention markers. Two cases were 
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‘incorrectly identified’ by lactate by the reassurance marker (< 5.4mmol/l), two by 
pH (> 7.25), and four by BD (< 8.0mmol/l). One case was ‘incorrectly identified’ by 
all reassurance markers. This suggested that lactate was as good a marker as pH and 
BD for the need of immediate intervention.
Table 5. Test characteristics of threshold values for fetal scalp pH ( ≤ 7.20), base deficit ( 
≥ 10 mmol/l) and lactate ( ≥ 6.6 mmol/l) in association with metabolic acidosis (pH < 7.05 
and base deficit > 12 mmol/l) at birth.
Metabolic acidosis
at birth* Lactate ≥ 6.6 pH ≤ 7.20 BD ≥ 10 pH ≤ 7.20 and BD ≥ 10 
Sensitivity (95%CI) 71 (61-81) 41 (30-52) 53 (42-64) 59 (50-68)
Specificity (95%CI) 87 (79-95) 86 (77-94 86 (78-94) 80 (72-88)
PPV (95%CI) 16 (8-24) 9 (2-16) 12 (5-19) 9 (6-12)
NPV2 (95%CI) 99 (97-100) 98 (95-100) 98 (95-100) 98 (95-100)
* pH < 7.05 and base deficit > 12 mmol/l in umbilical artery blood. PPV: Positive predictive value; NPV: Negative 
predictive value.
In the nine cases with metabolic acidosis at birth with a sampling-to-delivery interval 
≤ 60 minutes, there was no difference between lactate, pH, and BD in the number 
of cases ‘correctly identified’ by the marker for immediate intervention (six cases by 
lactate, pH, and BD) or ‘incorrectly identified’ by the reassurance marker (one case 
by lactate, none by pH, and one by BD). From the eight cases with a sampling-to-
delivery interval > 60 minutes, six (by lactate), one (by pH), and three cases (by BD) 
were ‘correctly identified’ by the marker for immediate intervention. One case was 
‘incorrectly identified’ by lactate, two by pH, and two by BD by the reassurance 
marker.
The majority of infants (12/17) who had metabolic acidosis at birth did not need to 
be admitted to intensive care and their neonatal course was uncomplicated. Of the 
five infants who were admitted to the neonatal intensive care, all but one appeared 
neurologically normal at discharge. This infant suffered from meconium aspiration 
and was severely anemic (Hb 4.9 mmol/l) at birth, apparently as a result of feto-
maternal hemorrhage. In this case, the FBS-lactate, pH, and BD values all correctly 
indicated the need for immediate intervention.
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Table 6.  Seventeen cases of metabolic acidosis at birth (umbilical artery pH < 7.05 
and base deficit > 12 mmol/l), tabulated in order of time interval between fetal blood 
sampling and delivery.
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1 18 8 AVD 8.3 7.02 15.1 9.0 9.3 7.04 15.7 7.7 -
2 20 6 AVD 11.9 7.05 13.9 8.6 11.5 7.03 18.5 6.3 + MAS
3 21 9 AVD 6.5 7.20 9.0 6.6 10.0 7.04 15.3 7.9 - -
4 23 9 AVD 3.4 7.08 12.4 8.6 6.2 6.99 16.4 9.1 - -
5 32 6 AVD 5.9 7.25 7.2 6.2 8.6 6.97 14.0 11.8 + -
6 35 7 AVD 6.6 7.23 10.1 5.5 7.3 6.97 17.6 8.8 - ARPKD
7 37 7 CS 9.4 6.99 15.1 10.0 6.2 6.89 18.0 12.0 + MAS
8 48 3 SVD 6.8 7.25 8.5 5.7 5.8 6.87 18.9 12.3 - -
9 60 7 CS 8.0 7.14 11.7 7.0 10.9 7.00 14.8 9.8 - GBS
10 63 5 CS 6.9 7.18 10.8 6.3 11.6 7.04 13.5 9.2 + MAS
11 70 7 CS 6.5 7.22 12.2 4.8 9.1 7.04 16.4 7.5 - GBS
12 72 8 CS 9.6 7.21 12.1 5.0 17.8 6.87 15.2 15.5 - -
13 75 9 CS 8.2 7.24 5.8 7.2 6.5 6.71 23.2 16.9 + GBS
14 82 8 CS 9.7 7.24 8.8 5.8 6.2 6.92 19.2 9.5 - -
15 91 9 CS 9.7 7.22 8.6 6.4 16.8 6.93 17.0 11.0 - -
16 94 9 SVD 4.0 7.28 5.6 6.1 9.6 6.97 14.2 11.6 - -
17 130 8 AVD 6.6 7.26 7.3 5.9 6.3 6.95 16.3 10.9 - -
Values correctly indicating immediate intervention at the time of sampling are green; values falsely indicating 
reassurance are red. AS, Apgarscore; AVD, assisted vaginal delivery; CS, cesarean section; SVD, spontaneous 
vaginal delivery; UA, umbilical artery; UV, Umbilical vein; NICU, neonatal intensive care unit; MAS, meconium 
aspiration syndrome; ARPKD, autosomal recessive polycystic kidney disease; GBS, group B streptococcus 
infection.
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Discussion
When Saling first introduced the technique of FBS, only pH was measured (2). pH 
alone provides little information about the duration and extent of hypoxia/metabolic 
acidemia. Transient respiratory acidemia with high pCO2 is a common feature of 
normal labor and correlates poorly with neonatal out- come (3,18). In contrast, 
severe metabolic acidosis represents tissue hypoxia and correlates well with neonatal 
multi-organ dysfunction and impaired neurodevelopment (4,19).
We used severe metabolic acidosis in umbilical artery blood as a proxy for poor 
clinical perinatal outcome. One objection to that might be that even marked acidosis 
may not necessarily be harmful as long as oxygenation is maintained. Although true 
under experimental conditions in which oxygenation can be artificially adjusted, 
in everyday obstetrics practice the common reason for metabolic acidosis is under-
perfusion on the maternal or fetal side, which is generally associated with poor 
oxygenation. Therefore, we feel that severe metabolic acidosis in umbilical cord 
blood is the best objective marker of poor neonatal outcome available.
Base deficit is used to quantify metabolic acidosis, as it accounts for both the carbon 
and the non-carbon buffering systems (5). Full blood gas analysis requires a relatively 
large amount of blood, which is difficult to obtain by FBS, therefore resulting in 
rather high failure rates (7). Apart from this practical drawback, for various reasons 
BD values may not be the best representative of fetal metabolic status. BD is not 
measured but is calculated using pH and pCO2 values. As CO2 can cross the 
placenta rapidly when perfusion is restored, pCO2 and therefore BD can fluctuate. 
In addition, air contamination in FBS may produce incorrect pCO2 levels and 
consequently false BD values. Moreover, the algorithms used for BD calculation 
are attuned to adult hemoglobin type, oxygen saturation, and temperature, and not 
to fetal blood composition, thus causing a systematic error in BD calculation (20). 
Although one can attempt to correct or exclude any unlikely values, in the absence 
of generally agreed rules to do so, we chose to report on all values as clinically used.
Lactate is the major end product of anaerobic metabolism and can be measured in a 
tiny amount of blood, which is practical in FBS. It has been well established by animal 
and human studies that fetal scalp blood lactate levels adequately represent lactate 
levels in the fetal central circulation and that fetal lactate production is endogenous 
in origin (21,22). In recent years, lactate has been shown to be a good predictor of 
severe morbidity in neonates and in intra-partum surveil- lance (12,17,23,24).
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Our study shows that lactate gradually increases with progressing metabolic acidosis 
and was a better marker than pH and/or BD, both of reassurance and of the need for 
immediate intervention.
The literature provides generally accepted cut-off values for pH, with pH >7.25 
indicating reassurance and pH ≤ 7.20 immediate intervention. This coincided in our 
study with reassurance at the 25th percentile and immediate intervention at the 15th 
percentile, indicating that 75% of cases were reassuring, 10% were inconclusive, and 
15% needed immediate intervention on the basis of pH alone. Although the validity 
of the traditional pH cut-off values may be questioned, given the distribution we 
chose to align our lactate and BD cut-off values on a percentile distribution equal to 
that of the generally accepted pH values.
For the purpose of the study, a fetal scalp blood BD value < 8.0mmol/l was considered 
reassuring. This threshold is based on studies in neonatal cord artery blood, as the 
literature does not report generally accepted BD cut-off values in fetal scalp blood. 
However, damaging metabolic acidosis is likely to occur only at BD values at birth 
of > 12–16mmol/l (4,25). Umbilical cord blood is known to be generally more 
acidic than fetal scalp blood, as the fetus becomes gradually more acidic during the 
course of labor and delivery (26). If one aims for prevention rather than prediction 
of metabolic acidosis at birth, BD in fetal scalp should be well below 12.0 mmol/l to 
provide reassurance. In our study, a fetal scalp BD < 8.0 mmol/L represented 75% of 
reassuring cases, a BD between 8.0 and 10.0 mmol/l the 10% inconclusive cases, and 
a BD ≥ 10.0 mmol/l the 15% fetuses in need for immediate intervention.
In our study a lactate value < 5.4 mmol/l indicated the 75% of reassuring cases, lactate 
between 5.4 and 6.6 mmol/l the 10% with inconclusive fetal status, and lactate ≥ 
6.6 mmol/l the 15% of fetuses in need of immediate intervention because of marked 
metabolic acidosis. These lactate cut-off values should not be taken to represent 
universal absolute threshold values for at least two reasons. Firstly, the cut-off values 
were estimated on the basis of a retrospective cohort and need confirmation in an 
independent prospective cohort. Secondly, in the absence of standard calibration 
techniques between laboratories and devices, our absolute values are valid only 
with the Rapidlab-860. Nonetheless, fetal lactate concentration not only has the 
theoretical advantage of measuring the product of metabolic acidosis directly as well 
as the practical advantage of smaller sample volume and fewer failures, but, as our 
study shows, it also holds the promise of better test characteristics compared with 
pH, BD, and (pH+BD) combined.
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Intra-partum cardiotocography is a screening test which has high sensitivity to detect 
fetuses at risk of hypoxemia and subsequent acidosis but rather poor specificity (1). 
FBS may either provide reassurance or provide additional proof that immediate 
delivery is needed. In our study, FBS was per- formed in 11% of all deliveries, 
reflecting the high level of suspicion in an academic training hospital that a fetal heart 
rate trace is non-reassuring. The use of FBS in obstetric routine varies widely, from 3 
to 15% in the Netherlands (27) and Sweden (28). To ensure that the threshold values 
for lactate are valid in both high- and low-risk populations, prospective validation in 
these populations is needed.
A lactate value < 5.4 mmol/l indicated reassuring fetal status, whereas a 
value≥6.6mmol/l indicated metabolic acidosis. If FBS is to provide reassurance, 
high specificity is important because the intra-partum cardiotocogram already has 
high sensitivity. As a marker for reassurance, lactate < 5.4, pH > 7.25, and (pH > 
7.25+BD < 8) had equal specificity (88%). BD alone performed less well (76%). 
Over- all, lactate excluding metabolic acidosis was a slightly better marker than pH, 
BD, and (pH+BD). If one aims to detect fetal metabolic acidosis severe enough to 
require immediate intervention, the sensitivity of the lactate cut-off needs to be high 
in order not to miss fetuses with metabolic acidosis.
As a marker of severe fetal metabolic acidosis, our study shows that lactate ≥ 6.6 
mmol/l and a BD≥10mmol/l have greater sensitivity than the traditionally used pH ≤ 
7.20 (Table 5). Overall, lactate to detect metabolic acidosis was a better marker than 
pH, BD, and (pH+BD). Lactate seemed to precede the fall in pH, especially when 
the time interval between sampling and delivery exceeded 60 minutes (Table 6). 
From animal studies in the ovine fetus, it is known that after repetitive hypoxic 
insults, pH is restored to normal within minutes of recovery, whereas lactate remains 
increased for hours (29). This suggests that lactate, as a marker for fetal status, is less 
sensitive to the sampling-to-delivery interval than are pH and BD.
As both the lactate concentration and BD are indicative of metabolic acidosis, a 
strong correlation between the two variables would be expected. A previous study 
in 2 554 single- ton babies reported a strong correlation between cord blood lactate 
and BD (r=0.83) (10). In our study, the correlation between lactate and BD in fetal 
scalp and cord blood was significant, but smaller than expected (r=0.48 and r=0.56, 
respectively). Several factors may have contributed to this:
1) Our data reflect a population of fetuses at risk for metabolic acidosis, whereas the 
study by Gjerris also included cord blood data from uncomplicated deliveries (10).
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2) The weaker correlation between lactate and BD in FBS compared to cord blood 
in our study may be explained in part by FBS sampling errors, including mixture 
with tissue fluid or air, which may have affected the calculated BD. The chance 
of admixture was present in our study, especially because FBS required 35µl and 
median sampling time was five minutes.
3) Calculated BD values were not corrected for fetal hemoglobin or temperature, 
even in the case of maternal fever.
4) Lactate values in FBS represent an admixture of lactate values from various blood 
compartments, the concentration being highest in plasma, lower in hemolyzed 
blood, and lowest in whole blood with intact erythrocytes (30).
5) Lactate values in FBS may represent an admixture with extracellular and even 
amniotic fluid; amniotic fluid is rich in lactate, also in the absence of fetal acidosis. 
The chance of contamination is likely to be smaller when small sample volumes are 
needed and sampling time is short, as is the case if only lactate is measured (9).
In conclusion, the lactate concentration in fetal scalp blood correlates with both 
pH and BD. The test characteristics that provide either reassurance or indication 
for immediate delivery seem to be better for lactate than for pH, BD, or the latter 
two combined. As lactate analysis is easier, faster, and more often successful than full 
blood gas analysis, fetal scalp blood lactate is an attractive alternative to full blood 
gas analysis during labor.
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Abstract
Background: Point-of-Care (POC) lactate testing of fetal scalp blood lactate 
is used as an alternative for pH analysis. Lactate measurements have not been 
standardized and values vary with each device used. The aim of this study was 
to evaluate the performance of two POC lactate meters for intrapartum use.
Methods: Analytical performance of StatStrip Lactate (Nova Biomedical) 
and Lactate Pro (Arkray) was evaluated using CLSI EP10. Both POC meters 
were compared with our lactate reference method (RapidLab 860; Siemens 
Healthcare Diagnostics) using fetal scalp and neonatal cord blood. Deming 
regression analysis was performed.
Results: StatStrip Lactate coefficients of variation (CVs) were 5.1%, 5.0%, 
and 2.6% at 0.9, 7.5, and 14.1 mmol/L lactate, respectively. CVs for Lactate 
Pro were 10.7%, 5.2%, and 5.7% at 1.7, 4.1, and 6.4 mmol/L lactate, 
respectively. Consecutive lactate measurements in 37 fetal scalp and 122 cord 
blood samples revealed different test characteristics for the two POC devices. 
In fetal scalp blood: StatStrip Lactate = 1.13*RapidLab - 0.39 (R2 = 0.907), 
and Lactate Pro = 0.95*RapidLab - 0.03 (R2 = 0.823). In cord artery blood: 
StatStrip Lactate = 1.08*RapidLab - 0.09 (R2 = 0.810), and Lactate Pro = 
0.72*RapidLab + 0.59 (R2 = 0.807).
Conclusions: Overall performance of both Lactate Pro and StatStrip Lactate 
was good, with StatStrip Lactate having smallest CVs and closest correlation 
to our reference method. Both StatStrip Lactate and Lactate Pro can be used 
as a lactate POC device for obstetric use.
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Introduction
In case of a non-reassuring or abnormal fetal heart rate pattern during labor, fetal 
blood scalp sampling (FBS) with pH analysis can be used to diagnose fetal hypoxia/
acidosis. FBS is associated with technical and practical problems. It is often difficult 
to obtain an adequate amount of blood for determination of pH or, preferably, full 
blood gas analysis. Modern apparatus still require 25 to 30 µL of blood for pH 
analysis and a minimum of 50 µL for a complete acid-base status. Air bubbles and 
inhomogeneous samples may jeopardize analysis. Furthermore, FBS with pH or 
complete acid-base status is time-consuming because of logistics of sampling and 
analysis (15-30 minutes) and has high failure rates (11-20%) (1-3). If only pH is 
measured, interpretation of the results may be difficult. A transient fall in pH may 
occur during normal labor as a result of temporary CO2 accumulation in the absence 
of metabolic acidosis or considerable neonatal morbidity. Persistent severe hypoxia/
ischemia leads to lactic acid accumulation, which is the major contributor to an 
increased base deficit (BD). This metabolic component of fetal acidemia is the most 
important indicator of subsequent neonatal morbidity (4-6).
Lactate measurement in fetal scalp blood may be an attractive alternative for pH/
full blood gas analysis in FBS. It requires only a tiny amount of blood (0.7-5.0 µl), 
failure rates are low (1.3-2.9%), and results of Point-of-Care testing (POC) devices 
are quickly available (13-60 seconds) (7). However, lactate measurements have 
not been standardized and values vary with the device used and the type of blood 
compartment sampled from (8-12) Therefore, test characteristics and lactate cut-off 
values in fetal scalp and neonatal cord blood have to be determined for each lactate 
measurement device.
The objective of this study was to compare the performance of POC lactate meters 
when applied to both fetal scalp and cord artery blood, using RapidLab as our lactate 
reference method.
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Materials and methods
Sample collection
The study was conducted with FBS and cord blood data obtained from women during 
labor at the Radboud University Nijmegen Medical Centre between December 2008 
and June 2009. The Radboud University Medical Centre is a tertiary referral centre 
with approximately 1500 low, medium and high-risk deliveries per year. Deliveries are 
managed by residents or midwives supervised by obstetricians. Cardiotocograms are 
classified and interpreted according to the guidelines of the International Federation 
of Gynecology and Obstetrics (13). FBS is performed on indication by the obstetric 
caregiver in case of intermediary or abnormal cardiotocography trace. The frequency 
of FBS in our institution is around 11% (14).
The technique of FBS was carried out as previously reported (15). After the 
incision in the fetal scalp, blood was collected in a 125 ml heparinized capillary 
tube (OmniLabo, Breda, the Netherlands), and send to the central laboratory for 
immediate analysis.
To systematically evaluate neonatal condition, umbilical cord blood gas analysis 
from both artery and vein is performed routinely. The cord is double clamped 
immediately after birth and punctured with a 19-gauge needle attached to a 125 µl 
heparinized capillary tube. After removal of the needle, the samples are closed and 
sent to the central laboratory for immediate analysis of full blood gas and lactate. 
For the purpose of this study paired umbilical blood samples from 145 consecutive 
deliveries were obtained during a three-month period. Only data from the umbilical 
artery were used in the analysis, assuming it to reflect fetal condition best. Umbilical 
vein results were used to verify correct sampling. To exclude mix up of samples or 
samples both coming from the same vessel, only sample pairs were used in which 
arterial pH was at least 0.02 lower than venous pH (16).
Approval from the University Ethics Committee was sought but was waved due to the 
fact that this study was solely and anonymously performed to test the performance of 
the lactate meters. Lactate values were not available for clinical management. 
Measuring devices
Because of the limited amount of fetal scalp blood, two POC lactate testing devices, 
potential candidates for use in our institution, were selected for evaluation.  The two 
POC lactate testing devices evaluated in this study were the StatStrip Lactate (Nova 
Biomedical, Waltham, MA, USA) and the Lactate Pro (Arkray, Kyoto, Japan). The 
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blood gas analyzer RapidLab 860 (Siemens Healthcare Diagnostics, Deerfield, IL, 
USA) was used to perform full blood gas analysis and served as a lactate reference 
method. The RapidLab 860 uses a lactate biosensor containing lactate oxidase. 
Analysis of lactate and full blood gas requires a minimum of 65 µL The StatStrip 
Lactate and Lactate Pro are hand-held single-use electrochemical test strips devices. 
Both meters utilize an amperometric method using an enzymatic reaction with 
lactate oxidase and potassium ferricyanide as an electron mediator. Sampling volume 
for Lactate Pro is 5.0 mL, while StatStrip Lactate uses 0.7 mL.
Analytical performance
To get an overall impression of performance of the Lactate Pro and StatStrip Lactate, 
lactate concentrations were determined at three different levels according CLSI EP10. 
Commercial controls, Rapid QC (Siemens Healthcare Diagnostics, Deerfield, IL, 
USA), were used. Total coefficients of variation were determined based on within-
day and between-day variation. Analytical performance was evaluated further using 
cord artery and fetal scalp blood in a comparison study.
Measurements in fetal scalp and cord artery blood
Three sequential lactate measurements were performed on Lactate Pro, StatStrip 
Lactate and RapidLab 860 as soon as the cord and fetal scalp blood samples arrived 
in the laboratory. The sequence was the same for all samples analyzed in this study. 
On the RapidLab 860 a full blood gas analysis was concomitantly performed. The 
results of sequential lactate measurements in both cord artery and FBS samples were 
compared as follows: RapidLab 860 versus i) Lactate Pro and ii) StatStrip Lactate. 
Regression was determined between: i) Lactate (RapidLab) and pH; ii) Lactate Pro 
and pH; iii) StatStrip Lactate and pH; iv) Lactate (RapidLab) and BD; v) Lactate Pro 
and BD; vi) StatStrip Lactate and BD.
Statistics
Correlation coefficients (R2) between the different methods were determined using 
Deming regression analysis. Student’s t test for paired samples, two tails, was used to 
compare paired differences. A p-value <0.05 was considered significant.
Computations were performed using EP EvaluatorTM 8.0 (D.G. Rhoads Associates 
Inc., South Burlington, USA) and SPSS 15.0 (SPSS Inc, Chicago, USA).
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Results
Analytical performance of POC devices
Performing CLSI EP10 at three different lactate levels yielded different mean lactate 
values. For RapidLab mean values were 0.9, 2.7 and 11.0 mmol/L. For StatStrip 
Lactate mean values were 0.9, 7.5, and 14.1 mmol/L, while for Lactate Pro mean 
values were 1.7, 4.1, and 6.4 mmol/L. Total coefficients of variation (CVs) for 
RapidLab were 5.5%, 2.7% and 5.2% at 0.9, 2.7 and 11.0 mmol/L, respectively. 
CVs for StatStrip Lactate were 5.1%, 5.0%, and 2.6% at 0.9, 7.5, and 14.1 mmol/L 
lactate, respectively. CVs for Lactate Pro were 10.7%, 5.2%, and 5.7% at 1.7, 4.1, 
and 6.4 mmol/L lactate, respectively.
Results in fetal scalp blood
During the study period 33 women underwent FBS during labor. In 6 women FBS 
was performed twice. In 1 woman FBS was performed three times. Intra-partum 
characteristics of 33 mother and baby pairs were as follows: average maternal age was 
32.7 years; 17 women (52%) were nulliparous and 16 (48%) were parous; 32 women 
(97%) had a singleton and 1 (3%) had a twin pregnancy. Gestational age ranged 
from 37.0 till 42.3 weeks. Spontaneous onset of labor occurred in 17 women (42%) 
and labor was induced in 16 women (48%). Spontaneous vaginal delivery occurred 
in 14 women (42%), 17 (52%) had vacuum-extraction, and cesarean section due to 
dystocia was performed in 2 women (6%). All neonates had an Apgarscore after 5 
minutes of 8 or higher. Birth weight ranged from 2560 till 4608 g.  No complications 
due to the FBS procedure were reported. In total 40 FBS samples were obtained. 
Lactate levels ranged from 1.6 till 6.7 mmol/L using RapidLab. Two results by 
StatStrip Lactate and 1 by Lactate Pro were considered invalid due to insufficient 
sample volume. These and their corresponding samples for the other meters were 
removed from further calculations. The tests results from the two POC devices and 
the reference method (RapidLab 860) were strongly correlated. Coefficients (R2) for 
StatStrip Lactate and Lactate Pro were 0.907 and 0.823, respectively (Figures 1-4). 
Results from Deming regression analysis are shown in Figures 1 and 2. For Lactate 
Pro (Figure 1): slope = 0.95 (95% CI ranging from 0.70 to 1.20) and intercept = 
-0.03 (95% CI ranging from -0.81 to 0.75). For StatStrip Lactate (Figure 2): slope 
= 1.13 (95% CI ranging from 0.99 to 1.26) and intercept = 0.39 (95% CI ranging 
from -0.85 to 0.07). Student’s t analysis between paired samples showed a significant 
difference between RapidLab and Lactate Pro (p = 0.032) and a non-significant 
difference between RapidLab and StatStrip Lactate (p = 0.453).
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Figure 1. Deming regression lines in fetal scalp blood for RapidLab 860 (X-axis) versus 
Lactate Pro.  Regression and correlation (R2) are depicted. Lines of identity and 
regression are indicated. Dashed lines indicate ± 2 SD.
 
 
Figure 2. Deming regression lines in fetal scalp blood for RapidLab 860 (X-axis) versus 
StatStrip Lactate.  Regression and correlation (R2) are depicted. Lines of identity and 
regression are indicated. Dashed lines indicate ± 2 SD.
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Results in cord artery blood
During the study period paired umbilical artery and vein samples were obtained 
from 145 consecutive deliveries. After pH validation 20 paired samples were 
excluded (16). A further three samples were removed due to inadequate sample 
volume. After exclusions, 122 samples were available for analysis. The intra-partum 
characteristics in this group were as follows: average maternal age was 30.5 years; 
60 women (49%) were nulliparous and 62 (51%) were parous; 116 women (95%) 
had a singleton and 6 (5%) a twin pregnancy. Gestational age ranged from 25.3 
till 42.0 weeks. Spontaneous onset of labor occurred in 54 women (44%), labor 
was induced in 56 women (46%) and a planned cesarean section was performed in 
12 (10%). Spontaneous vaginal delivery occurred in 85 (70%) women, 14 (11%) 
had a vacuum-extraction and cesarean section due to dystocia was performed in 
9 women (7%). Two neonates (2%) were delivered by primary breech extraction 
and 118 (96%) had an Apgarscore after 5 minutes ≥ 8. Four neonates (3%) had an 
Apgarscore after 5 minutes ≤7. Birth weight ranged from 777 till 4750 g. Lactate 
levels ranged from 1.6 till 14.5 mmol/L using RapidLab. Both StatStrip Lactate and 
Lactate Pro correlated strongly with the reference method (RapidLab 860), with 
coefficients (R2) of 0.810 and 0.807 respectively (Figures 3 and 4). Results from 
Deming regression analysis are shown in Figures 3 and 4. For Lactate Pro (Figure 3): 
slope = 0.72 (95% CI ranging from 0.61 to 0.83) and intercept = 0.59 (95% CI 
ranging from
 0.12 to 1.06). For StatStrip Lactate (Figure 4): slope = 1.08 (95% CI ranging from 
0.91 to 1.26) and intercept = -0.09 (95% CI ranging from -0.81 to 0.62). Student’s 
t analysis between paired samples showed a significant difference between RapidLab 
and Lactate Pro (p <0.001) as well as between RapidLab and StatStrip Lactate (p = 
0.001).
heinis-layout.indd   68 08/02/2018   15:20
69
Analytical performance of point of care lactate testing devices
C
ha
pt
er
 4
Figure 3. Deming regression lines in cord artery blood for RapidLab 860 (X-axis) 
versus Lactate Pro.  Regression and correlation (R2) are depicted. Lines of identity and 
regression are indicated. Dashed lines indicate ± 2 SD.
 
Figure 4. Deming regression lines in cord artery blood for RapidLab 860 (X-axis) versus 
StatStrip Lactate.  Regression and correlation (R2) are depicted. Lines of identity and 
regression are indicated. Dashed lines indicate ± 2 SD.
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Discussion
POC lactate test strip meters seem attractive for obstetric use because of the small 
sample size and rapid generation of results. Previous studies have evaluated POC 
meters for fetal scalp blood lactate assessment during labor (12;17-20). However, 
except for one (18), these studies have used neonatal cord blood for evaluation of 
the devices, and not fetal scalp blood obtained during labor. This study has evaluated 
the performance of a lactate meter using fetal scalp blood as well as neonatal cord 
artery blood.
When testing analytical performance of Lactate Pro and StatStrip Lactate using 
commercial control material, we observed large differences (up to 7.7 mmol/l) 
between absolute mean values at the three different concentration levels. These 
discrepancies might be caused by the fact that the matrix of these control materials 
is different from human blood. Analytical performance and coefficients of variation 
of the Lactate Pro was evaluated in a previous study using Maine standards at two 
different levels (12). In this study by Ridenour and co-workers’ differences in mean 
values are also observed, although they were less profound compared to our results. 
Ridenour and colleagues also found smaller coefficients of variation for Lactate 
Pro compared to our study, namely 4,0% at low (3.2 mmol/L) and 3.2% at high 
(10.4 mmol/L) levels (12). This might be caused by the fact that different control 
material was used compared to this study. These discrepancies show that commercial 
control material of non-human origin cannot be used to compare different POC 
lactate devices. Moreover, no gold standard for lactate measurement is available. This 
hampers interpretation of data. Standardization of lactate measurements is needed to 
eliminate these huge differences between different devices.
Deming regression analysis using fetal scalp blood showed good correlations between 
Lactate Pro as well as StatStrip Lactate and our reference method as shown in Figures 
1 and 2. StatStrip Lactate yielded the best correlation. However, we observed 
differences in regression lines when using Lactate Pro and StatStrip Lactate. Both 
devices showed a slope and intercept in comparison with RapidLab 860. The slope 
and intercept were smallest when using Lactate Pro. However, Student’s t analysis of 
paired samples showed a significant difference between RapidLab and Lactate Pro 
(p=0.032) while a non-significant difference between RapidLab and StatStrip Lactate 
was observed (p=0.453). When cord artery blood was used similar correlations 
between Lactate Pro, StatStrip Lactate and our reference method are obtained (R2 
= 0.807 and 0.810, respectively). The regression line of StatStrip Lactate from cord 
blood samples was comparable to the one found with fetal scalp blood (Figures 2 and 
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4). However, the regression line of Lactate Pro in cord artery blood differed from fetal 
scalp blood (Figures 1 and 3): y = 0.72x + 0.59 and y = 0.95x - 0.03, respectively. 
Similar discrepancies were found by others. In the study by Ridenour and colleagues, 
in which lactate in cord artery blood is analyzed using Nova Lactate Plus and Lactate 
Pro, similar differences in regression lines were observed.(12) This phenomenon is 
also observed by Nordström and co-workers who also used two different devices, i.e. 
Lactate Pro and Accusport for measurements in cord blood (21). Reference material 
in order to standardize the different lactate methods (e.g lactate measurements in 
plasma, hemolyzed blood or whole blood with intact erythrocytes), is not present. 
This lack of standardization is the most probable explanation for the fact that different 
regression lines are observed when different lactate measuring devices are used.
Surprisingly, we also found different regression lines when blood from different 
sources (fetal scalp versus cord blood) were used. This phenomenon is more profound 
when using Lactate Pro. Obtaining blood from the umbilical cord after birth is much 
easier than deriving blood from the fetal scalp. Fetal scalp blood is a mixture of blood 
and a variable amount of tissue fluid. This might be an explanation for the observed 
differences.
In conclusion, this study shows that caution should be taken when interpreting 
results from lactate measurements obtained from different devices and different 
blood sources. We have shown that both StatStrip Lactate and Lactate Pro can be 
used as a POC device for lactate measurements in fetal scalp and cord artery blood. 
StatStrip Lactate showed the best test characteristics, with smallest CVs, the closest 
correlation to and the highest agreement with our reference method. No significant 
difference between lactate values in FBS measured with StatStrip Lactate and our 
reference method was found.
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Abstract
Introduction: Point-of-Care testing of fetal scalp blood lactate is used as an 
alternative for pH analysis in fetal scalp blood sampling (FBS) during labor. 
Lactate measurements are not standardized and values vary with each device 
used. The aim of this study was to evaluate StatStrip Lactate (SSL) in the 
clinical setting in comparison to lactate (RLL) and pH (RLpH) by RapidLab.
Materials and methods: We obtained 323 FBS samples from 139 women. 
Parallel sampling of SSL and RLL/RLpH was performed in 247 samples. 
Outcome measures were the agreement and discrepancy rates between SSL, 
RLL and RLpH and the failure rate of all three methods. We constructed a 
Bland-Altman graph to assess the variability between the measurements across 
the range of values. The discrepancy rates between methods were compared 
using previously established cut-off values for SSL indicating reassurance 
(<5.7 mmol/L) and immediate delivery (>7.0 mmol/L) to those for RLpH 
(<7.20 and >7.25)
Results: SSL showed excellent agreement with RLL (R2=0.742) and poor 
agreement with RLpH (R2=0.204). Failure rates for SSL, RLL and RLpH 
were 7%, 43% and 23% respectively. Using the cut-off values for reassurance 
and immediate delivery, the discrepancy rates between SSL and RLpH were 
14% and 5% respectively.
Conclusions: SSL is a reliable test to measure lactate in FBS at a low failure 
rate. As there are discrepancies between SSL and RLpH and the cut-off values 
have not yet been evaluated prospectively regarding intervention rates and 
neonatal outcome, we recommend using SSL in addition to pH in FBS.
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Introduction
Fetal scalp blood sampling (FBS) is used in addition to a non-reassuring intra partum 
cardiotocogram (CTG) to assess fetal acidosis. FBS with pH analysis has been 
considered gold standard but has some major drawbacks; a relatively large amount 
of blood is needed (35 to 100 µL) and the logistics of sampling and analysis are 
time consuming (15-30 minutes) with high failure rates (11-20%) (1, 2). Moreover, 
handling of the sample, aerobic contamination and processing affect pH results. 
Lactate measurement in FBS is an attractive alternative. Persistent hypoxia/ischemia 
leads to lactate accumulation and metabolic acidosis, which is the most important 
indicator of subsequent neonatal morbidity (3, 4). Several studies, including 
randomized controlled trials have shown that scalp blood lactate has similar or better 
predictive properties in identifying short-term neonatal morbidity than fetal pH, 
without affecting the rate of metabolic acidosis at birth or operative deliveries for 
suspected fetal distress (5-7).
Point of care testing (POC) for lactate has several advantages. It requires a tiny amount 
of blood (0.7-5.0 µl) and results are rapidly available (13-60 seconds) at a low failure 
rate (1-3%) (2, 8, 9). However, POC lactate measurements are not standardized and 
values vary with the device used and the type of blood compartment sampled from 
(i.e. plasma, hemolysed blood or whole blood with intact erythrocytes). Therefore, 
the test characteristics and cut-off values in fetal scalp blood have to be established 
for each device. In a previous study, we compared the characteristics of two POC 
lactate devices, Lactate Pro (Akray, Kyoto, Japan) and StatStrip Lactate (SSL), in a 
laboratory setting, using the Rapid Lab blood gas analyzer as a reference method. 
As compared to the Lactate Pro, SSL showed a closer correlation with the reference 
method, better test characteristics, and a smaller coefficient of variation (CV) (10). 
The value of SSL for its use in the clinical setting remained to be evaluated.
The aim of this study was to investigate SSL for its use in FBS in a clinical setting. For 
this purpose, we assessed the agreement between SSL, lactate (RLL) and pH (RLpH) 
measured on the RapidLab blood gas analyzer. We also assessed the discrepancy rates 
between the methods using the previously established SSL cut-off values that served 
as indicators for both reassurance and immediate delivery.
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Materials and methods
We conducted a prospective observational study with SSL in FBS obtained from 
women with suspected fetal distress during labor. The study was performed at the 
Radboud University Medical Center between 13 February 2010 and 12 March 
2011. Included were women with a singleton fetus in vertex presentation and a 
gestational age of 34 weeks or over.  The study was approved by the University Ethics 
Committee (2009/345).
The Radboud University Medical Center is a tertiary referral center with approximately 
1500 deliveries per year (low, medium and high-risk). Deliveries are managed by 
midwives and residents supervised by obstetricians. Cardiotocograms (CTG’s) are 
classified and interpreted according to the guidelines of the International Federation 
of Gynecology and Obstetrics (11). FBS is performed in case of an intermediary or 
abnormal CTG trace, as interpreted by the obstetric caregiver. The percentage of 
deliveries in which FBS is performed is approximately 11 % (12).
FBS was carried out by standard technique (13). After incision of the fetal scalp, 
blood was collected in heparinized plastic capillaries. POC lactate was performed 
with the Statstrip Lactate (Nova Biomedical, Waltham, MA, USA), which is a hand-
held single-use device that utilizes 0.7 mL of blood and electrochemical test strips. 
After POCT lactate testing, the remaining sample was sent to the laboratory for 
immediate full blood gas and lactate analysis on a blood gas analyzer (RapidLab 860, 
Siemens Healthcare Diagnostics, Deerfield, IL, USA). This required samples of 50-
100 µl. If sampling volume is insufficient at best only pH is measured. Base deficit 
was calculated for the blood compartment [BD(B)], using the algorithm: BD (B) = 
(1 − 0.014 × ctHb)[cHCO3
− − 24.8) + (1.43 × ctHb + 7.7)(pH − 7.40)]. Clinical 
management was solely based on RLpH. Guidelines were as follows: RLpH ≥ 7.25 
normal; continue fetal monitoring and pH ≤ 7.20 acidemia; consider delivery. pH 
value between 7.20 and 7.25 pre-acidemia; repeated sampling after 30 minutes. For 
the purpose of this study we considered a SSL value ≤ 5.7 mmol/l indicative for 
reassuring fetal status and a SSL value ≥ 7.0 mmol/l representing acidemia.  These 
cut-off values were established by introducing the RL lactate cut-off values (5.4 and 
6.6 mmol/L) from a retrospective cohort into the formula: SSL = 1.13*RL - 0.39, 
which was generated from a comparison study of RL and SSL in 38 FBS samples 
(10, 12). The discrepancy rates were studied using cross-tabulation.
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Neonatal acid-base status was evaluated systematically through umbilical cord blood 
gas analysis from both artery and vein immediately after birth. For the purpose of this 
study only data from the umbilical artery (UA) were used in the analysis, assuming 
it to reflect fetal condition best. Severe metabolic acidosis at birth was defined as pH 
< 7.05 and BD > 12.0 mmol/l in UA blood (7).
Statistical analysis was performed with SPSS version 22 (IBM SPSS Inc, Armonk, 
New York). Relations between SSL, RLL and RLpH in FBS were tested using 
regression analysis. We constructed a Bland-Altman graph to assess the variability 
between the measurements across the range of values for SSL and RLL. Data are 
presented as medians with 95 (2.5–97.5) centile ranges.
heinis-layout.indd   79 08/02/2018   15:20
80
Chapter 5
Results
During the study period 1589 women delivered at the Radboud University Medical 
Center. FBS was performed in 139 (9%) women. The intra-partum characteristics of 
these mother-baby pairs are summarized in Table 1. There were no complications of 
the FBS procedure. There was a wide variance in the sampling to delivery interval, 
ranging from a few minutes till several hours. In 112 (35%) cases FBS was performed 
at full dilatation. Three percent of infants in the studied population had metabolic 
acidosis at birth.
Table 1. Intra partum characteristics of 139 mother and baby pairs.
Characteristic Number (%) or median (range)
Maternal age (years) 30 (19-41)
Nulliparous 111 (80%)
Gestational age (days) 278 (252-293)
Sampling to delivery interval (min)
Spontaneous vaginal delivery 
60 (10-482)
52 (37%)
Ventouse delivery
Cesarean section
ODFDa
52 (37%)
35 (25%)
44 (32%)
Birth weight (g) 3383 (2360-4375)
Five minute Apgar score < 7 2 (1%)
Metabolic acidosis at birthb 4 (3%)
Data are numbers and percentage of total (%), or medians with 2.5th and 97.5th centile. a Operative delivery for 
fetal distress. bpH < 7.05 and base deficit ≥ 12 mmol/l in umbilical artery blood.
From the 139 women, a total of 323 fetal scalp blood samples were obtained in 
which RLL and RLpH were measured (Figure 1). Parallel measurement of SSL 
was performed in 247 of these samples. SSL, RLL and RLpH analysis failed in 7% 
(17/247), 23% (73/323) and 43% (140/323) respectively. For further analysis, one 
sample was excluded due to a 30-minute time interval between SSL and RLL/RLpH 
measurement.
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Figure 1. Flowchart of the study population. *One sample was excluded due to a 30-
min interval between SSL and RLL/pH analysis. FBS, fetal scalp blood sampling; SSL, 
StatStrip® Lactate; RLpH, RapidLab® pH; RLL, RapidLab® Lactate.
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In 142 fetal scalp blood samples both SSL and RLL results were available. We found 
a strong agreement (R2 = 0.747) as shown in Figure 2. In 82% (117/142) of the 
samples SSL (≤ 5.7 mmol/l) correctly indicated the absence of lactemia (RLL ≤ 5.4 
mol/L). There was a discrepancy between SSL and RLL for these cut-off values in 6% 
(9/142) of the samples. In 5% (7/142) of the samples SSL (≥ 7.0 mmol/L) correctly 
indicated the presence of lactemia (RLL≥ 6.6 mmol/L). There was a discrepancy 
between SSL and RLL for these cut-off values in 2% (3/142) of the samples. A 
Bland-Altman graph analysis showed minimal variance between SSL and RLL, and 
a slight linear increase with increasing lactate concentrations, i.e., SSL measured 
slightly higher than RLL with increasing lactate values (Figure 3).
In 191 fetal scalp blood samples both SSL and RLpH results were available. Fetal 
scalp SSL values correlated poorly with scalp RLpH (Figure 4, R2 = 0.206). In 77% 
(148/191) of the samples SSL (≤ 5.7 mmol/l) correctly indicated the absence of 
acidemia (RLpH ≥ 7.25). There was a discrepancy between SSL and RLpH for these 
cut-off values in 14% (27/191) of the samples. From these discrepant samples, 15 
cases showed normal SSL values, whereas pH did not. In these cases, all but one 
RLpH value (7.08) indicated pre-acidemia (7.20-7.25). Twelve cases showed normal 
RLpH values, whereas SSL did not. Of these, SSL levels indicated pre-acidemia 
(5.7-7.0 mmol/L) and acidemia (≥ 7.0 mmol/L) in nine and three cases respectively.
In 3% (6/191) SSL (≥ 7.0 mmol/l) correctly indicated the presence of acidemia 
(RLpH ≤ 7.20). There was a discrepancy between SSL and RLpH for these cut-
off values in 5% (10/191) of the samples. In Table 2 these discrepant samples are 
presented in more detail. Five cases showed SSL values indicating acidemia, whereas 
RLpH did not. In these cases, RLpH values were within the normal to pre-acidemic 
range.  None of these infants had metabolic acidosis at birth. The five cases where 
RLpH indicated acidemia and SSL did not, SSL levels were all in the pre-acidemic 
range (5.7-7.0 mmol/l) except for case number nine. In this child, a scalp blood 
sample was taken within 26 minutes of birth. There was a large discrepancy between 
SSL (3.8 mmol/l) and RLpH (7.08) in this FBS sample. Further investigation of this 
case showed that a ventouse delivery was performed because of persistent bradycardia. 
In all cases SSL values were in line with the available RLL values, suggesting a correct 
lactate measurement rather than a false negative result in relation to RLpH.
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Figure 2. Scatterplot of 142 lactate determinations with Statstrip Lactate (SSL) and 
Rapidlab (RLL). Dashed lines correspond to cut-off values for reassurance (SSL ≤ 
5.7 mmol/L and RLL ≤ 5.4 mmol/L). Continuous lines correspond to cut-off values for 
immediate delivery (SSL ≥ 7.0 mmol/L and RLL ≥ 6.6 mmol/L).
Figure 3. Bland-Altman plot with a regression line (including 95% prediction intervals) 
of differences between lactate concentrations (mmol/L) as measured by Statstrip 
Lactate (SSL) and RapidLab (RLL). Slope and intercept are indicated.
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Figure 4. Scatterplot of 191 lactate determinations with Statstrip Lactate (SSL) and 
Rapidlab pH (RLpH). Dashed lines correspond to cut-off values for reassurance (SSL ≤ 
5.7 mmol/L and RLpH ≥ 7.25  mmol/L). Continuous lines correspond to cut-off values for 
immediate delivery (SSL ≥ 7.0 mmol/L and RLpH ≤ 7.20 mmol/L).
In 182 fetal scalp blood samples both RLL and RLpH results were available. Fetal 
scalp RLL values correlated poorly with scalp RLpH (R2 = 0.110). We observed 
discrepancies between RLL (≤ 5.4 mmol/l) and RLpH (≥ 7.25) in 17% (31/182) of 
the samples. For the cut-off values for RLL (≥ 6.6 mmol/L) and and RLpH (≤ 7.20) 
those were 7% (12/182). These numbers were comparable to the ones we observed 
between SSL and RLpH.
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Discussion
In this study, we tested the value of SSL for its use in FBS in a clinical setting. We 
found that the lactate level in fetal scalp blood is accurately measured by SSL at a 
much lower failure rate compared to RLpH and RLL. In the vast majority of cases 
SSL cut-off values provided correct information on fetal status.
Previous studies that have validated SSL showed reliable results (10, 19, 20). 
However, these studies only used cord blood, or a small number of fetal scalp samples 
and therefore do not adequately represent real labor ward conditions. To our best 
knowledge this is the first study that has evaluated a POC lactate device in a clinical 
setting with a large number of scalp blood samples. We found a strong agreement 
of SSL in comparison to RLL. This suggests that SSL is suitable for POC lactate 
analysis in FBS.
Measurement of SSL has a lower failure rate than RLpH/RLL. We detected a SSL 
failure rate of 7%. This is fairly high compared to literature (1-3%) (2,6,8). This 
might be due to the fact that our labor ward staff was not yet familiar with the device 
and that samples were not immediately repeated after failure. Recent experience with 
SSL on our ward shows that the failure rate can be reduced to nil by quick analysis 
of a second drop. The failure rate for RLpH and RLL analysis in our study was 23% 
and 43% respectively, which is in line with other studies: 10-20% for pH only and 
> 50% for simultaneous pH/lactate analysis (2). The required sample volume and 
the way the blood gas analyzer handles the sample can explain this large difference in 
failure rates between SSL and RLL/RLpH. Standard blood gas analyzers, including 
the RapidLab 860, require a large volume of 50-100 µL for determining pH and 
lactate results. If the sampling volume is too small, at best only pH is measured. SSL 
has the convenience of a very low sampling volume (0.7 µL). This indicates that SSL 
is an attractive tool in the obstetric setting.
FBS with pH and/or lactate analysis can be used to discriminate the fetus that tolerates 
labor well from the fetus with a developing acidemia in case of a non-reassuring 
CTG. As presented in other studies, we found that the correlation between SSL 
and pH in fetal scalp blood is poor and that discrepancies are quite common (14). 
As both parameters might reflect different aspects of a developing acidemia, one 
may question whether discrepancies should be considered as false positive or false 
negative test results, or that pH is not the correct gold standard. A low pH with a 
normal lactate can be due to: 1) Transient impairment of the carbon dioxide exchange 
following umbilical cord compression. 2) Early stage of a fast-developing acidosis. 
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A normal pH with a high lactate can be explained by: 1) Slow clearance of lactate 
from the fetal circulation and fast normalization of pH sometime after a hypoxic 
insult, 2) Early stage of a slowly developing acidosis, 3) Factors other than hypoxia, 
such as contamination of amniotic fluid or limited local perfusion as with caput 
formation (8, 12, 15, 16). Furthermore, the fetal acid-base balance is influenced by 
the administration of beta-mimetic drugs glucose, maternal hyperventilation and 
catecholamine concentrations (18). It therefore might be wise to perform parallel 
analyses of both pH and lactate in FBS, as they might mirror different stages of a 
developing asphyxia.
Concern has been raised that combined sampling (pH and lactate) might increase the 
rate of operative delivery for fetal distress, due to an increased rate of abnormal results 
compared to single tests. Liljestrom et al. showed that combined sampling results in 
a 66% operative delivery rate versus 95% if single testing is used (pH or lactate) (7, 
14). One may argue that the use of a test with a 20% failure rate is not justified. We 
identified 5% and 14% discrepancies between SSL and RLpH for the cut-off values 
for reassuring fetal status and immediate intervention, respectively. Because of these 
discrepancies and the lack of a randomized controlled trial comparing combined 
testing with single testing, we propose combined sampling to reduce the chance of 
missing fetal hypoxia. In order to avoid repeated sampling when pH analysis fails, 
clinical management in those cases is based on SSL only. A summary of the clinical 
guideline we have implemented in our labor ward is provided in Table 3.
Table 3. Clinical guidelines for fetal scalp blood sampling using pH and Statstrip Lactate 
(SSL)
Normal Borderline Abnormal
pH > 7.25 7.20 - 7.25 < 7.20
SSL (mmol/l) < 5.7 5.7 – 7.0 > 7.0
• If pH fails, clinical management is based on SSL result only
• In the borderline group, repeated sampling in 20-30 minutes is recommended
• In case of discrepancies (pH normal, SSL borderline/abnormal or vice versa); seek senior consultancy >> 
repeated sampling or delivery
The goal of FBS is to prevent adverse neonatal outcome. The commonly accepted 
thresholds for scalp pH are ≤ 7.20 and ≥ 7.25 for immediate delivery and reassuring 
fetal status. In a population of 486 fetuses in whom FBS was performed, we found 
that these values correspond to the 15th and 25th percentile respectively (12). In 
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analogy with this, the 75th and 85th percentile cut-off values for RLL are ≤ 5.4 
and ≥ 6.6 mmol/L (12). The cut-off values for SSL ≤ 5.7 and ≥ 7.0 mmol/L were 
established by regression analysis of RL and SSL in 38 FBS samples from a previous 
study of our group (10). The cut-off for SSL of 7.0 mmol/l is close to the cut-
off established by Ridenour et al. They compared Lactate Pro and Lactate Plus (an 
earlier version of SSL) with a lactate reference method using neonatal cord blood. 
Based on both regression and ROC curve analysis they found cut-offs to predict scalp 
pH < 7.20 at 7.0 and 6.8 mmol/l, respectively. They concluded that sensitivity and 
specificity of Lactate Pro and Lactate Plus for predicting acidosis are nearly identical, 
suggesting that there is no difference in the ability of the devices to predict acidosis 
but that different cut-offs for this purpose must be used. As expected and in line with 
Ridenour et al., there was poor agreement between SSL and RLpH (20). We found 
strong agreement and a low discrepancy rate between the POC device (SSL) and the 
reference method (RLL). To our knowledge this comparison has never been made 
in a clinical setting. Although the cut-off values for SSL need to be further tested 
prospectively in clinical outcome studies, the above suggests that thresholds defined 
for SSL seem to be adequate.
Several limitations can be identified in our study. Firstly, in 76 samples SSL analysis 
was not performed at all. This was probably due to the fact that our labor ward 
staff was not yet familiar with the device. Secondly, we were not able to relate the 
threshold values to neonatal outcome, as the time interval between FBS and delivery 
varied from 10 minutes to 8 hours. Our study design did not allow for such analysis 
as we did not use the SSL values for clinical management. This is the scope for 
future research. Thirdly, our population contained only a few samples representing 
fetal acidosis. However, the low prevalence of poor outcome is a common problem 
in evaluating tests for fetal well-being during labor. FBS is an important tool to 
exclude acidosis when the CTG is abnormal, as the intra partum CTG has a high 
false positive rate for this outcome.
In conclusion, we showed that SSL is a reliable test and can be used in daily 
obstetric practice for POC lactate testing in fetal scalp blood. SSL provides accurate 
information on fetal status in the vast majority of cases at a minimal failure rate. As 
there are discrepancies between SSL and RLpH and the cut-off values have not yet 
been evaluated prospectively regarding intervention rates and neonatal outcome, we 
propose combined testing of SSL and pH in FBS.
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Abstract
Introduction: To improve intra partum fetal monitoring in our hospital, we 
implemented two new procedures: ST-analysis of the fetal ECG and Point 
of Care (POC) lactate testing in fetal scalp blood sampling (FBS) in parallel 
with pH according to a new clinical guideline. In this study, we describe the 
two-year follow-up of these measures.
Materials and methods: We compared two birth cohorts with singleton 
vertex deliveries ≥ 36 weeks in which FBS was performed. Cohort one ranged 
from 2010-2011, cohort two from 2014-2016. We assessed maternal and 
neonatal data, including mode of delivery, birthweight, Apgar score, FBS and 
cord blood acid-base values. Main outcome measures were FBS failure rate, 
operative delivery rates and metabolic acidosis at birth. 
Results: Overall FBS usage remained stable with 137/1165 deliveries (12%) 
in cohort 1 and 253/2139 (12%) in cohort 2. The FBS failure rate decreased 
from 23 % to 2%, as did the number of samples per labor (from 2.3 to 1.6). In 
cases where FBS was performed, we found a significant decrease in ventouse 
delivery (from 37% to 27%) and a significant increase in spontaneous vaginal 
delivery (from 37% to 49%). Low Apgar score and neonatal metabolic 
acidosis remained stable. 
Conclusions: The implementation of STAN and POC lactate testing resulted 
in a tenfold decrease in FBS failure rate and fewer scalp samples per labor. This 
was associated with a higher proportion of spontaneous vaginal deliveries with 
comparable perinatal outcome.
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Introduction
Intra-partum cardiotocography (CTG) is a useful screening test for fetal hypoxia/
acidosis, but requires supplementary tests to avoid unnecessary operative delivery 
(1, 2). Many methods have been proposed for this purpose. The two best known 
and accepted ones are fetal blood sampling (FBS) and ST analysis of the fetal 
electrocardiogram (STAN). 
The use of FBS in addition to CTG is likely to reduce the rate of cesarean sections 
(CS), when compared with CTG surveillance only (3, 4). Traditionally, pH is the 
primary parameter measured in FBS. This is cumbersome because a relatively large 
amount of blood (30-50 µl) is needed. This leads to high sampling failure rates (up to 
20% have been reported) and may lead to a subsequent delay in clinical management 
(5). Moreover, when only pH is used, no differentiation is made between respiratory 
(CO2 accumulation) and metabolic academia (lactate acidosis), the latter being 
associated with poor neonatal outcome (6). Lactate measurement in FBS may be an 
attractive alternative to pH. Point of Care (POC) lactate testing devices need only 
a tiny amount of blood (0.7 -5µl), deliver fast results (13-60 seconds) with a high 
success rate (97-99%) (7).  A randomized controlled trial (RCT), comparing pH and 
lactate, showed significantly fewer failures with lactate analysis (1 versus 20%) and 
no differences in short term neonatal outcome or mode of delivery (8). 
STAN is a technique that detects changes in the ST segment of the fetal ECG (ST 
events) during labor, which are an indicator of fetal hypoxia (9). The occurrence 
of these ST events is interpreted together with CTG, as defined in the STAN 
clinical guidelines (10). Meta-analysis comparing STAN to CTG with or without 
FBS, confirms a lower rate of metabolic acidosis (RR 0.64, 95% CI 0.46-0.88), a 
reduction in the rate of FBS (RR 0.59, 95% CI 0.45-0.79) and a reduction in the 
overall rate of assisted vaginal delivery (RR 0.92, 95% CI 0.86-0.99). No reduction 
is shown in the rate of operative delivery for fetal distress, perinatal death, seizures 
and encephalopathy (11). Two studies have shown that in comparison to CTG with 
FBS, STAN is cost-effective (12, 13). 
To improve intra partum fetal monitoring in our hospital, we expanded our 
procedures and techniques for fetal monitoring. STAN was installed in all delivery 
rooms by March 2012.  At that time, FBS pH measurement as an adjunct to CTG 
was used at a frequency of around 11% of deliveries, but with a failure rate of around 
20-30%. In order to reduce this unacceptably high failure rate, we implemented 
POC lactate testing in conjunction with FBS pH measurement. 
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In this paper, we describe the results of the two-year follow-up post implementation 
of these measures and the impact on FBS success, delivery intervention rates and 
perinatal outcome. 
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Materials and methods
The study was conducted by comparing two cohorts with singleton vertex deliveries 
at the Radboud University Medical Center from ≥ 36 weeks of gestation. Cohort 
I ranged from February 13th 2010 until March 13th 2011. Cohort II ranged from 
February 5th 2014 until February 5th 2016. 
The Radboud University Medical Center is a tertiary referral center with approximately 
1500 deliveries per year (low, medium and high-risk). Deliveries are managed by 
clinical midwives and residents, supervised by obstetricians. Intra partum fetal 
monitoring is performed by CTG with the option to perform FBS in case of an 
intermediary or abnormal CTG trace, as interpreted by the obstetric caregiver. 
The expanded fetal monitoring protocol was introduced from March 2012 and 
included the following:
1. STAN®, Neoventa Medical, Gotenborg Sweden was introduced in all six 
delivery rooms. The classification of CTG tracings and ST-events is performed 
according to the STAN clinical guidelines (10). FBS in case of STAN use is 
recommended in the following three situations: (i) start of STAN® registration 
with an intermediary or abnormal CTG trace; (ii) abnormal CTG trace for more 
than 60 minutes during the first stage without ST events; and (iii) poor ECG 
signal quality in the presence of an intermediary or abnormal CTG trace (9).
2. FBS with POC lactate testing using Statstrip® Lactate (SSL) (Nova Biomedical, 
Waltham, MA, USA). SSL is a hand-held single-use device that utilizes 0.7 µL 
of blood and electrochemical test strips. The result is available in 13 seconds. 
FBS is carried out with the standard technique with the use of Rocket® disposable 
sampling kit (Rocket Medical, Washington USA). After incision of the fetal scalp, 
blood is collected in two heparinized plastic capillaries. In the first sample, POC 
lactate testing is performed with SSL. The second sample is sent to the laboratory for 
pH analysis on a blood gas analyzer (RapidLab 348, Siemens Healthcare Diagnostics, 
Deerfield, IL, USA). The result is available after 10-15 minutes. Because the SSL cut-
off values were based on a small series of measurements, and not yet prospectively 
tested regarding intervention rates and neonatal outcome, we use combined testing 
of SSL and pH in the following manner: If pH fails, clinical management is based on 
the SSL result only. In case of discrepancies (pH normal, SSL borderline/abnormal 
or vice versa) the team was instructed to consult a senior obstetrician to decide what 
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to do: intra uterine resuscitation, repeated sampling or initiate immediate delivery. 
Cut-off values for SSL were: < 5.7 mmol/L reassuring; continue fetal monitoring, 
5.7-7.0 mmol/L borderline; repeated sampling within 30 minutes and > 7.0 mmol/L 
abnormal; consider immediate delivery (14). For pH, the corresponding cut-off 
values were: > 7.25 (reassuring), 7.25 and 7.20 (borderline) and < 7.20 (abnormal).
In order to keep the FBS rate at a reasonable level and the efficacy as high as possible, 
our local guideline regarding intra partum fetal monitoring was revised. The 
indication for FBS has become stricter and depends on the type of fetal monitoring 
used: CTG only or STAN. The new local guideline is based on the national one by 
the Dutch Society of Obstetricians and Gynecologists (NVOG) and provides an 
association between CTG classification and subsequent clinical management (15). 
For monitoring with CTG only: normal tracings – no actions required; suboptimal 
tracings – continue monitoring and try to alleviate possible causes (such as reducing 
maternal temperature, discontinuing oxytocin, changing maternal position, treating 
maternal hypotension etc.); abnormal tracings – try to alleviate possible causes. If 
reversal is not shown, perform FBS with immediate delivery in mind; pre-terminal 
tracing – immediate delivery. For monitoring with STAN: in order to prevent 
unnecessary CS when significant ST-events are present in the first stage of labor, 
FBS can be performed at the discretion of the obstetrician in those situations. The 
rationale behind this is that in the majority of FBS samples (56%) taken in the 
presence of significant ST-events a pH ≥ 7.25 is found (16). 
For both cohorts, maternal and neonatal data were derived from our local electronic 
patient file system. This included maternal age, parity, gestational age, mode of 
delivery, birth weight and Apgar score, as well as FBS and cord blood data. The 
success rate of FBS was defined as having a result with either method (pH and/
or SSL). Metabolic acidosis at birth was systematically evaluated by cord blood 
sampling immediately after delivery from both the umbilical artery and vein. The 
umbilical vein specimen results were used to verify correct sampling. Only data from 
the umbilical artery specimens were used in the analysis under the assumption that 
these reflect fetal condition best. Cord blood samples were analyzed on the Rapid 
Point 500 (Siemens Healthcare Diagnostics, Deerfield, IL, USA). Base deficit was 
calculated for the blood compartment [BD(B)], using the algorithm: BD (B) = (1 − 
0.014 × ctHb)[cHCO3
− − 24.8) + (1.43 × ctHb + 7.7)(pH − 7.40)]. Severe metabolic 
acidosis at birth was defined as pH < 7.05 and BD > 12.0 mmol/l in cord artery 
blood (8).
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Statistical analysis was performed with SPSS version 22 (IBM SPSS Inc, Armonk, 
New York. Data are presented as numbers with percentages or medians with 95 
(2.5–97.5) centile ranges. For normally distributed data, Student t-test, and for 2x2 
tables, Chi square test was used. For skewed data, Mann-Withney U test was used. A 
p value < 0.05 was considered as a statistically significant difference.
As confirmed by the Medical Ethics Committee of Radboud UMC, Nijmegen, the 
Netherlands, our study only involves existing clinical patient data and imposes no 
changes in general practice. Therefore, according to the Declaration of Helsinki, no 
ethical approval was required. 
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Results
The total number of singleton vertex deliveries beyond 36 weeks in cohort one was 
1165 and 2139 in cohort two. FBS was performed in 137 (12%) deliveries in cohort 
one and 253 (12%) in cohort two. The intra partum characteristics of the mother 
and baby pairs are summarized in Table 1. The number of FBS samples per labor 
decreased from 2.3 in cohort one, to 1.6 in cohort two. Maternal characteristics and 
neonatal outcome were comparable. No complications of the FBS procedure were 
reported. The FBS success rate increased from 77 % in FBS cohort one to 98% in 
FBS cohort two. There was a significant decrease in ventouse delivery resulting in a 
significant increase in spontaneous vaginal delivery.
Table 1. Intra partum characteristics of mother and baby pair cases where FBS was 
performed. 
Characteristic
FBS Cohort 1
n=137
FBS Cohort 2
n=253 P-value
Maternal age (years) a 30 (19-41) 31 (21-41) 0.17
Nulliparous b 110 (80) 183 (72) 0.12
Gestational age (days) a 278 (252-293) 273 (252-294) 0.36
Number of FBS samples c 315 (2.3) 414 (1.6) < 0.0001
Successful FBS b, d 250 (77) 405 (98) < 0.00001
Spontaneous vaginal delivery b 50 (37) 123 (49) 0.026
Ventouse delivery 52 (37) 69 (27) 0.04
Cesarean section 35 (25) 60 (24) 0.72
Birth weight (grams) a 3383 (2360-4375) 3245 (2240-4329) 0.05
Five minute Apgar score < 7 b 2 (1) 11 (4) 0.10
Metabolic acidosis at birth b, e 4 (3)* 9 (4)# 0.61
Data are medians with 2.5th and 97.5th centile a, numbers and percentage of total (%) b, or numbers and numbers 
per patient c. d Successful analysis of total FBS samples e pH < 7.05 and base deficit > 12 mmol/l in umbilical artery 
blood. * Time interval FBS-delivery: 26-580 minutes. # Time interval FBS-delivery: 18-320 minutes
In cohort two, the total of FBS samples was 414 from 259 labors. The success rate of 
FBS-pH analysis was 83 %. From the 70 (17%) cases where pH analysis failed, SSL 
analysis failed in six cases and was not performed in three cases. Of the remaining 
61 cases where SSL data was available, 29 (48%) women had a spontaneous vaginal 
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delivery, 15 (25%) a ventouse delivery and 16 (26%) an emergency CS. From these 
61 cases, one infant had metabolic acidosis at birth. The FBS sampling to delivery 
interval in this case was 189 minutes.
In 321 fetal scalp blood samples both SSL and pH results were available (Figure 
1). In 91% (292/321) of the samples there was concordance between SSL and pH 
regarding the presence (SSL > 7.0 mmol/l and pH < 7.20) or absence of acidemia 
(SSL < 5.7 mmol/L and pH > 7.25). There was a discrepancy between SSL and pH 
regarding the presence (15 samples) and absence (14 samples) of acidemia in 9% 
(29/321) of the samples.
Figure 1. Scatterplot of 321 lactate determinations with Statstrip Lactate (SSL) and pH. 
Dashed lines correspond to cut-off values for reassurance (SSL 5.7 mmol/L and pH 7.25). 
Continuous lines correspond to cut-off values for immediate delivery (SSL 7.0 mmol/L 
and pH 7.20). Open dots are FBS samples from infants with metabolic acidosis at birth.
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Table 2 shows the nine individual cases of metabolic acidosis at birth (umbilical artery 
pH < 7.05 and BD > 12 mmol/l) from cohort 2, tabulated in order of FBS sampling 
to delivery interval. Acute obstetric complications including placental abruption, 
uterine rupture, or prolapsed cord, were absent. In the five cases where the sampling 
to delivery interval was < 60 minutes, pH was more often abnormal than SSL. In the 
four cases where the sampling to delivery interval exceeded 60 minutes, SSL and pH 
results were normal. Neonatal course was uneventful in all infants.
Table 2. Nine cases of metabolic acidosis at birth (umbilical artery pH < 7.05 and base 
deficit > 12 mmol/l), tabulated in order of time interval between fetal blood sampling 
and delivery. In case of multiple FBS samples, the values of the last FBS sample are 
shown.
No
Time 
interval AS 5’
FBS
SSL
FBS
pH
UA
Lactate
UA
pH
UA
BD
Mode of
delivery
1 0:18 9 6.1 7.16 9.9 7.02 15.0 VE
2 0:18 8 FA 7.15 10.2 6.91 16.9 VE
3 0:33 8 4.4 7.32 12.7 7.01 15.2 VE
4 0:35 8 4.2 7.23 NA 6.98 12.8 VE
5 0:36 9 3.5 7.21 14.2 6.81 21.3 CS
6 1:04 10 2.7 7.22 8.0 7.03 13.9 VE
7 1:19 8 4.9 7.28 NA 7.02 14.2 VE
8 1:30 8 3.3 7.28 NA 7.02 13.7 SV
9 1:46 7 2.6 7.30 10.8 6.86 14.4 VE
AS; Apgar score, SSL; Statstrip Lactate, UA; umbilical artery, BD; base deficit, FA; failed analysis, NA; not 
available VE; vacuum extraction, SV; spontaneous vaginal delivery, CS; Cesarean section. 
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Discussion
After implementation of the expanded fetal monitoring protocol we found an equal 
number of deliveries in which FBS was performed, a reduction in repeated FBS 
per labor, a much higher FBS success rate, and a higher proportion of spontaneous 
vaginal deliveries with comparable perinatal outcome. 
FBS is used as an adjunct to CTG in order to identify the fetus at risk for hypoxia/
acidosis. Its use varies between countries, hospitals and obstetric care providers. In 
the Netherlands FBS is performed in 3 to 15 % of deliveries (17). Although there 
was a decrease in the number of scalp samples per labor from 2.3 to 1.6 in our study, 
we did not see a reduction in overall FBS usage as reported in other studies (9,11). 
An explanation for this could be that the residents, midwives and obstetricians on 
our ward were not completely familiar with the STAN technique and therefore did 
not dare to entirely rely on the STAN clinical guidelines. Moreover, our guideline 
allowed for FBS to be performed in case of significant ST events in the first stage of 
labor, as it has been reported that the majority (56%) of FBS samples taken in those 
situations show a pH ≥ 7.25 (16). Secondly, the reduction in the number of FBS 
per woman suggests that the clinicians relied more on ST-analysis after a reassuring 
FBS-result. Therefore, the implementation of ST-analysis could explain both the 
absence of a reduction in overall FBS usage as well as the reduction in the number 
of repeated FBS per labor.
FBS as an adjunct to STAN is somewhat controversial and some argue that FBS 
should be abandoned entirely (18). However, false negative results have been reported 
with STAN use (19-21). In fact, the STAN clinical guidelines were modified due to 
the reports of these false negative results to include recommendations for situations 
in which additional fetal information is needed (10). The STAN clinical guidelines 
do not explicitly mention FBS as a possible means to provide this additional 
information, the national guideline on fetal monitoring issued by the Dutch 
Society of Obstetricians and Gynecologists (NVOG) does recommend FBS in those 
situations (15). Our updated local guideline is based on this national guideline and 
recommends a stricter use of FBS to make it as efficient as possible. FBS is an invasive 
test with rare but potentially serious complications including scalp abscess, bleeding 
and infection. These risks are comparable to the risk with the use of a scalp electrode 
(22). Moreover, the positive predictive value is low as the a priori risk of an acidotic 
fetus is low. The absence of a reduction in overall FBS usage found in our study, 
underlines the need for more training and critical discussion between colleagues. We 
also think that there should be a greater involvement of the supervising obstetrician 
heinis-layout.indd   103 08/02/2018   15:20
104
Chapter 6
prior to the decision to perform FBS, as this has shown to increase the pretest 
probability of detecting fetal acidosis and reduce the operative delivery rate for fetal 
distress, as well unnecessary FBS (23).  Moreover, a large prospective observational 
study from Norway evaluating the clinical use of STAN, showed a low proportion of 
metabolic acidosis (0.8%) with a restricted use of FBS (2.4%) (24).
By implementing SSL for POC lactate testing in FBS, we have reduced the FBS-failure 
rate to 3.5%. Recent experience with SSL on our ward shows that the failure rate 
can be reduced to nil by quick analysis of a second blood drop. This is in accordance 
with the literature where failure rates of 1-3% have been reported (8, 25, 26). Prior 
to the implementation of SSL, the FBS-failure rate in our institution, was at an 
unacceptably high level of 20-30%, which is much higher than the 10-20% reported 
in the literature (26-28). This high failure rate may have resulted in large sampling 
to result intervals and therefore in a delay in clinical management as Tufnell and co-
workers previously reported (5). We decided to perform lactate testing before pH 
analysis, as SSL delivers a result in 13 seconds. If the value is abnormal, arrangements 
for delivery can be made while waiting for the pH result, thereby keeping a potential 
delay in management as low as possible. In our opinion, the CTG abnormalities 
indicating FBS should be severe enough to warrant immediate delivery. This means 
that if there is no result, immediate delivery should be performed. This could mean 
that a high FBS failure rate might also result in unnecessary operative intervention. 
With the use of SSL, we obtained a FBS result in 60/69 cases where pH analysis 
failed. Assuming that in those cases operative delivery would have been performed 
because of no pH result, one might argue that the availability of an SSL has prevented 
operative delivery in 44/60 cases. 
Concern has been raised that combined sampling (pH and lactate) might increase 
the rate of operative delivery for fetal distress. Wiberg et al. reported in their RCT 
comparing pH with lactate in FBS a significantly higher proportion of abnormal 
results in the lactate group. In fact, this was the only statically significant difference 
in the trial. One might therefore argue that combined testing of pH and lactate 
would be a more reliable risk indicator of metabolic acidosis. The authors however, 
discouraged this as it might lead to an increased rate of abnormal results, and thereby 
the rate of operative interventions (8). Liljestrom et al, showed that combined testing 
resulted in a 66% operative delivery rate versus a 95% rate if single testing was used 
(29). This is in accordance with our study, where we showed that combined testing 
of lactate and pH results in a 12% increase in spontaneous vaginal deliveries, a 10% 
reduction in ventouse deliveries with a comparable cesarean section rate.
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FBS with pH and/or lactate analysis can be used to discriminate the fetus that tolerates 
labor well from the fetus with a developing acidemia in case of a non-reassuring 
CTG. The relationship between lactate and pH in fetal scalp blood is known to 
be poor and discrepancies are quite common (14, 27, 29, 30). As both parameters 
might reflect different aspects of a developing acidemia, one may question whether 
discrepancies should be considered as false positive or false negative test results, or 
that pH is not the correct gold standard. We thought that it might therefore be wise 
to perform parallel analyses of both pH and lactate in FBS, as they might mirror 
different stages of a developing asphyxia. In a previous study from which FBS cohort 
one originated, we identified 5% and 14% discrepancies between SSL and pH for 
the cut-off values for reassurance (5.7 mmol/L and 7.25) and immediate delivery 
(7.0 mmol/L and 7,20) (14). Assuming pH with cut-offs of 7.20 and 7.25 to be 
the gold standard, a 14% discrepancy rate for immediate intervention could mean 
that cases of imminent hypoxia might be missed (“false negatives”). On the other 
hand, a large discrepancy rate for reassurance might increase intervention rates (“false 
positives”). In the present study, the discrepancy rates between SSL and pH for these 
cut-off values were equally distributed at 5% and 4% respectively. In addition to the 
absence of randomized controlled trials comparing combined with single testing, 
the use of SSL and pH in parallel with the use of these cut-off values seems to be 
justified.
Several limitations can be identified in our study. Firstly, this is a single center 
retrospective cohort study. Although data was collected and checked from multiple 
data sources from our laboratory and obstetric department, inaccurate record keeping 
or misclassification could have influenced outcome data. Secondly, we did not 
monitor the type of fetal monitoring used (e.g STAN or CTG only) and the indication 
for FBS, therefore we could not determine what caused the increase in FBS usage 
specifically. Thirdly, both FBS cohorts contained only a few samples representing 
fetal acidosis. However, the low prevalence of poor outcome is a common problem in 
evaluating tests for fetal well-being during labor. FBS is an important tool to exclude 
acidosis when the CTG is abnormal or, in case of STAN monitoring, if the physician 
is uncertain of fetal well-being and additional information is required. 
In conclusion, we showed that the implementation of an expanded fetal monitoring 
protocol incorporating STAN and FBS lactate testing in conjunction with pH, 
resulted in an unchanged overall FBS usage, a tenfold decrease in FBS failure rate 
and a lower rate of FBS per labor. This was associated with a higher proportion of 
heinis-layout.indd   105 08/02/2018   15:20
106
Chapter 6
spontaneous vaginal deliveries with comparable perinatal outcome. A continuous 
focus on the quality of intrapartum surveillance, by ongoing discussion and training 
is needed to reduce FBS usage and improve maternal and neonatal outcome.
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General discussion
The ideal method for intra partum fetal monitoring would be simple, noninvasive, 
and applicable for all women in labor, irrespective of gestational age. Furthermore, 
the method should ideally satisfy three criteria. Firstly, the method should give an 
early warning (when the baby is only pre-acidemic), to provide time for the clinician 
to deliver the baby without putting the mother at unnecessary risk. Secondly, system 
feedback should be clear (“do we have a problem? yes or no”) and easy to follow 
guidelines should be available. Thirdly, the test should be able to identify the non-
hypoxic fetuses so unnecessary intervention can be avoided. Neither FBS, nor STAN 
fulfill all of these criteria, but their integrated use could be the way to move forward.
In this thesis, we have elaborated further on these challenges, aimed at guiding best 
practice. In this chapter, a discussion of the main findings of this thesis is given, as 
well as the implications for clinical practice and future research. The main findings 
of this thesis are:
• The inter observer agreement on CTG patterns prior to FBS is poor. There is 
a relatively high chance that clinicians would disagree on the need to perform 
FBS. To ensure that FBS is as efficient as possible, the indication should be more 
strictly described in a well implemented guideline providing a clear association 
between the different CTG classifications and subsequent management 
(Chapter 2).
• The lactate concentration in fetal scalp blood correlates with both pH and base 
deficit. The test characteristics providing either reassurance or an indication for 
immediate delivery seem to be better for lactate than for pH, base deficit, or 
the latter two combined. As lactate analysis is easier, faster, and more often 
successful, fetal scalp blood lactate is an attractive alternative to full blood gas 
analysis in FBS (Chapter 3).
• Laboratory evaluation shows that StatStrip Lactate can be used as a Point of 
Care (POC) device for lactate measurements in FBS. In comparison to Lactate 
Pro, StatStrip Lactate shows the better analytical performance characteristics, 
with the lowest coefficients of variance, the closest correlation to and the highest 
agreement with our reference method (Chapter 4).
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• Clinical evaluation shows that Statstrip Lactate accurately measures the lactate 
level in FBS with a minimal failure rate. Using the experimentally established 
cut-off values, Statstrip Lactate provides accurate information on fetal status in 
the vast majority of cases. The correlation between lactate and pH is poor and 
discrepancies are common. As both parameters might reflect different aspects 
of a developing acidemia and the cut-off values have not yet been evaluated 
and prospectively tested regarding intervention rates and neonatal outcome, we 
propose combined testing of Statstrip lactate and pH in FBS (Chapter 3 and 5).
• The implementation of an expanded fetal monitoring protocol containing 
combined testing of Statstrip lactate and pH, ST-analysis of the fetal ECG and an 
updated clinical guideline, results in an increase in FBS usage, a tenfold decrease 
in FBS failure rate, fewer scalp samples per labor and a higher proportion of 
spontaneous vaginal deliveries with comparable perinatal outcome (Chapter 6).
• A continuous focus on the quality of intrapartum surveillance, by critical 
discussion, training and involving the supervising obstetrician prior to the 
decision to perform FBS is needed to reduce FBS usage and improve maternal 
and neonatal outcome. (Chapter 2 and 6).
CTG and FBS
FBS is performed as an additional test in case of CTG suspected fetal distress. As 
the interpretation of a non-reassuring or abnormal tracing CTG suffers from high 
inter-and intra-observer variation, the indication for FBS also carries a high risk of 
observer disagreement. In Chapter 2, we describe to what extent clinicians agreed on 
clinical management options when CTG abnormalities occurred.
Considerable variation in the classification of CTG patterns was found. Observers 
agreed poorly with each other and fair to good with themselves on CTG classification 
and clinical management. They achieved the highest agreement on abnormal CTG 
patterns and on the clinical management option “continue monitoring.” Clinical 
midwives and registrars agreed better than the obstetricians. One may speculate 
on possible explanations: (i) registrars are all trained in the same teaching hospital, 
whereas obstetricians may have different backgrounds; (ii) clinical midwives and 
registrars are more “bed-side” than obstetricians and have more current experience 
than obstetricians; (iii) the observer category size differed in the various groups (four 
obstetricians, three registrars and two clinical midwives), increasing the probability 
that the fair to good agreement of the midwives was due to chance. It is likely that the 
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level of experience and type of profession influences CTG interpretation. Westerhuis 
et al. showed differences indicative of higher rates of agreement in more experienced 
and recently educated professionals (1).
The observers assessed the CTG patterns using the FIGO/STAN guidelines, while 
the CTG patterns stem from a period of time in which the FIGO/STAN guidelines 
were not used in the labor ward. Probably FBS was performed on more liberal 
indications at that time (i.e. for reassurance on fetal condition before active pushing 
is started). Even with the use of the FIGO/STAN guidelines, the interpretation, i.e. 
classification of CTG patterns is difficult. This has clinical implications regarding the 
use of FBS and fetal monitoring with CTG. FBS is an invasive test and the a priori 
chance for a fetus suffering from acidosis is low. To ensure that FBS is as efficient 
as possible, we think the indication for its use should be more strictly described. 
Moreover, physicians should be aware of the fact that there is a relatively high chance 
their colleagues might classify a CTG pattern differently or choose another clinical 
management strategy. The success of FBS depends on correct CTG-interpretation 
and appropriate intervention (or non-intervention), which highlights the importance 
of critical discussion between colleagues and the need for a well implemented 
guideline providing a clear association between the different CTG classifications and 
subsequent management options.
Critics of FBS argue that it is an invasive test with potentially serious complications 
and that its predictive value for poor perinatal outcome is very low (2, 3). Both 
aspects need to be seen in perspective. Firstly, despite the large numbers of FBS 
performed worldwide over the last four decades, only a few serious complications 
have been reported. Reviewing the literature twelve papers reported a total of 37 cases 
of severe complications following FBS (4). Recent data from a large maternity unit 
in Denmark where FBS was used in over 25000 patients during a ten-year period, 
no such severe complications were observed (5). Secondly, the majority of babies 
depressed at birth, requiring intubation and ventilation, are not significantly hypoxic 
or acidemic. Instead their poor condition has other causes, such as sepsis, meconium 
aspiration and trauma. It would be unreasonable to expect such outcomes to be 
predictable by measuring the acid-base status of the fetus. Moreover, the prevalence 
of metabolic acidosis severe enough to cause brain damage is rare: 3/1000 (6). 
Therefore, no matter how excellent the test will be, the positive predictive value will 
still be low. On the flip side, the negative predictive value will be very high. Therefore, 
the main value of FBS is not to detect acidosis, but to exclude it when the CTG is 
abnormal. FBS samples from 486 fetuses born in our obstetric unit shows that the 
vast majority of pH values within the normal range (Chapter 3). This indicates that 
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despite CTG abnormalities, most of the time a relatively normal pH and lactate is 
found in FBS. Therefore, if the only concern in labor is fetal hypoxia and the labor 
is otherwise progressing well, a normal pH or lactate from a free flowing FBS makes 
significant metabolic acidosis extremely unlikely, thus allowing additional time to 
achieve a vaginal delivery rather than requiring an urgent CS.
FBS has the potential to reduce the caesarean section rate. To show this, CTG with 
FBS needs to be compared to CTG alone. There is only one RCT that has made 
this direct comparison; the Denver trial of 1979. This was a three-armed RCT of 
695 high-risk pregnancies. 232 were monitored by auscultation alone, 233 by CTG 
alone, and 230 by CTG and FBS. There was a 7% difference in CS rate in favor of 
CTG with FBS (7). This difference was not statistically significant. Since the Denver 
trial a number of other trials were performed to test the efficacy of CTG. These 
11 trials are consolidated in a recent meta-analysis from 2013 (8). The conclusion 
was that continuous CTG during labor is associated with a reduction in neonatal 
seizures, but no significant differences in cerebral palsy, infant mortality or other 
standard measures of neonatal well-being. However, continuous CTG was associated 
with an increase in caesarean sections and instrumental vaginal births. Critics of FBS 
refer to this meta-analysis when they argue that there is no shown benefit of FBS 
as an adjunct to CTG. However, the comparison was made between RCT’s with 
access to FBS in all arms and RCT’s without FBS. I.e. intermittent auscultation 
with or without FBS was compared to CTG with or without FBS. If we look at 
the same data from the older version of this meta-analysis, the data were presented 
in a different way. Intermittent auscultation was compared to CTG alone and to 
CTG with FBS. Thus, allowing an indirect comparison between CTG with FBS 
and CTG without FBS.  As compared to intermittent auscultation, the CS rate is 
almost doubled, whereas in the studies where FBS was used in addition to CTG, this 
increase was much less profound (9). Although high level evidence is lacking, this 
implies that FBS might reduce the CS rate with 6 to 7 %.
Lactate, pH or both?
When Saling first introduced the technique of FBS, only pH was measured (10). The 
measurement of pH alone provides little information about the duration and extent 
of hypoxia/metabolic acidemia. Transient respiratory acidemia with high pCO2 is a 
common feature of normal labor and correlates poorly with neonatal outcome (6, 
11). In contrast, severe metabolic acidosis represents tissue hypoxia and correlates 
well with neonatal multi-organ dysfunction and impaired neurodevelopment (12, 
13).
heinis-layout.indd   116 08/02/2018   15:20
117
General discussion and conclusions
C
ha
pt
er
 7
Base deficit (BD) is used to quantify metabolic acidosis, as it accounts for both the 
carbon and the non-carbon buffering systems (14). Full blood gas analysis requires 
a relatively large amount of blood, which is difficult to obtain by FBS, therefore 
resulting in rather high failure rates (15). Apart from this practical drawback, for 
various reasons BD values may not be the best representative of fetal metabolic status. 
BD is not measured but is calculated using pH and pCO2 values. As CO2 can 
cross the placenta rapidly when perfusion is restored, pCO2 and therefore BD can 
fluctuate. In addition, air contamination in FBS may produce incorrect pCO2 levels 
and consequently false BD values. Moreover, the algorithms used for BD calculation 
are attuned to adult hemoglobin type, oxygen saturation, and temperature, and not 
to fetal blood composition, thus causing a systematic error in BD calculation (16).
Lactate is the major end product of anaerobic metabolism and can be measured in 
a tiny amount of blood, which is practical in FBS. It has been well established by 
animal and human studies that fetal scalp blood lactate levels adequately represent 
lactate levels in the fetal central circulation and that fetal lactate production is 
endogenous in origin (17, 18). In recent years, lactate has been shown to be a good 
predictor of severe morbidity in neonates and in intra-partum surveillance (19, 20). 
As described in Chapter 3, the lactate concentration in FBS gradually increases with 
progressing metabolic acidosis and was a better marker than pH and/or BD, both for 
reassurance and for the need for immediate intervention. As lactate analysis is easier, 
faster, and more often successful than full blood gas analysis, fetal scalp blood lactate 
is an attractive alternative to full blood gas analysis during labor.
As described in Chapter 3, a lactate value < 5.4 mmol/l indicated the 75% of 
reassuring cases, lactate between 5.4 and 6.6 mmol/l the 10% with inconclusive fetal 
status, and lactate ≥ 6.6mmol/l the 15% of fetuses in need of immediate intervention 
because of marked metabolic acidosis. These lactate cut-off values should not be 
taken to represent universal absolute threshold values for at least two reasons. Firstly, 
the cut-off values were estimated on the basis of a retrospective cohort and need 
confirmation in an independent prospective cohort. Secondly, in the absence of 
international standards and reference material for calibration alignment between 
laboratory analyzers and point of care (POC) devices, our absolute values are valid 
only with the Rapidlab-860, which is a large blood gas analyzer requiring a minimum 
sampling volume of 50 microliters.
POC lactate testing devices are attractive for their use in FBS because of the low 
sampling volume (0.7–5.0/L), rapid results (13–60 s) and low failure rates (1.3%–
2.9%) (15). However, due to lack of standardization, test characteristics and lactate 
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cut-off values in FBS have to be determined for each measurement device (21-23). 
As described in Chapter 4, we evaluated the analytical performance of two POC 
lactate testing devices, Lactate Pro (LP) and Stastrip Lactate (SSL) and compared 
them to Rapidlab 860 (RL), which served as a reference method. We found that 
both SSL and LP can be used as a POC device for lactate measurements in FBS. SSL 
showed the smallest coefficient of variance, the closest correlation to and the highest 
agreement with RL. With the use of the regression equation generated with 38 FBS 
samples from this study, we converted the RL lactate cut-off values 5.4 and 6.0 to 
SSL (5,7 and 7.0). In the laboratory setting SSL showed the best characteristics. As 
described in Chapter 5, the value of SSL for its use in the clinical setting remained 
to be evaluated. For this purpose, we assessed the agreement of SSL, lactate (RLL) 
and pH (RLpH) measured on the RapidLab blood gas analyzer. We also assessed the 
discrepancy rates between the methods using the previously established SSL cut-off 
values that served as indicators for both reassurance and immediate delivery. We 
showed that the lactate level in FBS is accurately measured by SSL with a much 
lower failure rate compared to RLpH and RLL. SSL cut-off values provided correct 
information on fetal status in the vast majority of cases.
We also found a poor correlation between SSL and RLpH and that discrepancies are 
quite common. As both parameters might reflect different aspects of a developing 
acidemia, one may question whether these discrepancies should be considered false 
positive or false negative test results, or that pH is not the correct gold standard. 
A low pH with a normal lactate can be due to transient impairment of the carbon 
dioxide exchange following umbilical cord compression or an early stage of a fast-
developing acidosis. A normal pH with a high lactate can be explained by: (1) 
slow clearance of lactate from the fetal circulation and fast normalization of pH 
sometime after a hypoxic insult; (2) an early stage of a slowly developing acidosis; 
(3) factors other than hypoxia, such as contamination of amniotic fluid or limited 
local perfusion as occurs with caput formation (24, 25). Furthermore, the fetal acid– 
base balance is influenced by the administration of beta- mimetic drugs, glucose, 
maternal hyperventilation and catecholamine concentrations (17, 26). As lactate 
and pH might mirror different stages of a developing asphyxia and the SSL cut-off 
values have not yet evaluated prospectively regarding intervention rates and clinical 
outcome, it might be wise to perform parallel analysis of both pH and lactate.
Concern has been raised that this combined sampling might increase the rate of 
operative delivery for fetal distress, due to an increased rate of abnormal results 
compared with single tests. Liljestrom et al. showed that combined sampling results 
in a 66% operative delivery rate vs. 95% if single testing is used (pH or lactate) 
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(27). One may argue that the use of a test with a 20% failure rate is not justified. As 
described in Chapter 5, we identified 14% and 5% discrepancies between SSL and 
RLpH for the cut-off values for reassuring fetal status and immediate intervention 
respectively. Because of these discrepancies and to reduce the chance of missing 
fetal hypoxia, we propose combined testing of SSL and RLpH. To avoid repeated 
sampling when pH analysis fails, clinical management in those cases is based on SSL 
only.
STAN and FBS
Currently, there is intense debate as to whether STAN has a place in contemporary 
obstetric practice, or whether its use should be discouraged and discontinued. The 
role of FBS in combination with STAN is also subject of discussion. Some find it 
counterproductive that FBS is used to confirm or supplement the results obtained 
by STAN. Others do not believe in STAN and advocate continued use of CTG and 
FBS.
The first randomized controlled trials (RCTs) conducted in Europe showed a great 
promise with regard to STAN in reducing operative delivery rates and neonatal 
metabolic acidosis (28, 29), whereas subsequent studies have produced conflicting 
results with regarding to these outcomes (30, 31). The largest RCT on STAN in 
the United States in 2015 has concluded that the use of STAN neither reduced 
operative deliveries nor improved neonatal outcome (32). A subsequent meta-
analysis which included six RCTs including the US trial showed that ST analysis 
was not associated with a reduction in operative deliveries for fetal distress, but did 
show a 40% reduction in FBS usage and a 36% reduction in the rate of neonatal 
metabolic acidosis. However, the authors question the clinical significance of the 
observed reduction in metabolic acidosis and point out that no effect on the most 
meaningful outcomes, including cesarean delivery, severe acidemia at birth, or 
encephalopathy. They conclude that there is not enough evidence to justify the use 
of STAN in contemporary obstetrics (33, 34). Other opposers of STAN argue that 
it is a non-intuitive method which occupies a lot of intellectual capacity (35). This 
may lead to the focus on the screen and the complex algorithm, instead of the focus 
on proactive support and the progress of labor.
After the publications of the US trial, the debate regarding the efficacy of STAN 
has intensified. Advocates of STAN argue that the results of the US trial may not be 
representative for European clinical practice, as there were a number of fundamental 
differences between the US trial and the European trials. In the US trial, a three tier 
instead of a four-tier cardiotocography (CTG) classification and ST-action system 
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was used. FBS use was absent, and the recruitment rate was very low. On average, 
there were nine inclusions per institution per month, in contrast to 15 - 135 in 
the five European trials. The low inclusion rate of only two per week in large units 
with many obstetric care givers may have hampered adequate exposure to the new 
monitoring technique. Data from the European trials shows that the results in 
favor of ST analysis were more pronounced in the second half of the trials, which 
suggests a continuing learning process (36). Moreover, longitudinal data from several 
hospitals shows that after the introduction of STAN, metabolic acidosis at birth fell 
over the course of several years by 50 – 75%, without an increase in instrumental 
deliveries (37). The latter data suggest that an introduction of ST analysis in the 
labor ward may have resulted in a considerably better outcome than expected on 
the basis of the trials. An explanation for this could be that the introduction of the 
new device may have resulted in more attention towards CTG interpretation, as 
structured CTG classification and training are an essential part of the ST package. 
The better than expected outcome in the conventional arm of the Dutch RCT may 
also point towards an improved CTG interpretation (i.e. the ‘Hawthorne effect’). 
Moreover, the automatic detection and depiction of (significant) ST changes 
forces the clinician to interpret the CTG pattern and ST events to determine 
clinical management. In other words, in case of possible deterioration of the fetal 
condition the clinician is obliged to make a documented decision. Analysis of cases 
with neonatal encephalopathy despite the use of STAN monitoring, revealed that 
human error was responsible for 13 out of 14 cases. These included: error in CTG 
interpretation, failures in considering the wider clinical picture such as the presence 
of meconium, chorioamnionitis, failure to progress in labor as well as injudicious use 
of oxytocin infusion and delays in intervention (38). It seems to be human error that 
blunts the effectiveness of the STAN technology.
As described in Chapter 6, the FBS-failure rate in our institution was at a level of 
30%. In order to reduce this unacceptably high failure rate, we introduced a new FBS 
sampling method and implemented the combined testing of SSL and pH in FBS. In 
addition, STAN was installed in all delivery rooms and our local clinical guideline 
concerning fetal monitoring was updated. The implementation of these expanded 
measures for fetal monitoring, resulted in an increase in FBS usage, a tenfold decrease 
in FBS failure rate and a lower rate of FBS per labor. This was associated with a higher 
proportion of spontaneous vaginal deliveries with comparable perinatal outcome.
FBS as an adjunct to STAN is somewhat controversial and some argue that FBS 
should be abandoned entirely (2). However, false negative results have been reported 
with STAN use (39-41). In fact, the STAN clinical guidelines were modified due to 
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the reports of these false negative results to include recommendations for situations 
in which additional fetal information is needed (42). The STAN clinical guidelines 
do not explicitly mention FBS as a possible means to provide this additional 
information, the national guideline on fetal monitoring issued by the Dutch 
Society of Obstetricians and Gynecologists (NVOG) does recommend FBS in those 
situations (43). Our updated local guideline is based on this national guideline and 
recommends a stricter use of FBS to make it as efficient as possible. The positive 
predictive value is low as the a priori risk of an acidotic fetus is low. Although there 
was a decrease in the number of scalp samples per labor from 2.3 to 1.6 in our study, 
we did not see a reduction in overall FBS usage, which underlines the need for 
more training and critical discussion between colleagues. We also think that there 
should be a greater involvement of the supervising obstetrician prior to the decision 
to perform FBS, as this has shown to increase the pretest probability and reduce the 
CS rate of for fetal distress, as well as instrumental birth and unnecessary FBS (44).
In the Netherlands FBS is performed in 3 to 15 % of deliveries (45). As described 
in Chapter 6, we found an increase in FBS usage from 12 to 19% after the 
implementation of our expanded fetal monitoring protocol. This increase in FBS 
usage was higher than reported in the literature and implies a more liberal use of 
FBS, i.e. for reassurance on fetal condition before active pushing is started. It could 
also be explained by the convenience and high success rate of SSL compared to the 
cumbersome procedure to obtain a pH result in FBS. The threshold to perform FBS 
might be lower when the clinician knows that an SSL result can be easily obtained 
when there is CTG-suspected fetal distress. In contrast, if there is high chance of 
failure, as is the case with pH analysis, it is likely that the clinician would waive 
FBS altogether in those situations. Another explanation for the increase in our 
study could be that the residents, midwives and obstetricians on our ward were not 
completely familiar with the STAN technique and therefore did not dare to entirely 
rely on the STAN clinical guidelines. Moreover, our guideline allowed for FBS to be 
performed in case of significant ST events in the first stage of labor, as it has been 
reported that the majority (56%) of FBS samples taken in those situations show a 
pH ≥ 7.25 (46). Secondly, the reduction in the number of FBS per woman suggests 
that the clinicians relied more on ST-analysis after a reassuring FBS-result. Therefore, 
the implementation of ST-analysis could explain both the increase in overall FBS 
usage as well as the reduction in the number of repeated FBS.
As described in Chapter 6, we managed to reduce the FBS-failure rate to 3.5% by 
implementing combined testing of SSL and pH in FBS. Recent experience with SSL 
on our ward shows that the failure rate can be reduced to nil by quick analysis of a 
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second blood drop. This is in accordance with the literature where failure rates of 1-3% 
have been reported (15, 19, 47). Prior to the implementation of combined testing, 
the FBS failure rate was 30%, which is much higher than the 10-20% reported in 
the literature (15, 17, 48). This high failure rate may have resulted in large sampling 
to result intervals and therefore in a delay in clinical management as Tufnell and co-
workers previously reported (49). We decided to perform lactate testing before pH 
analysis, as SSL delivers a result in 13 seconds. If the value is abnormal, arrangements 
for delivery can be made while waiting for the pH result, thereby keeping a potential 
delay in management as low as possible. In our opinion, the CTG abnormalities 
indicating FBS should be severe enough to warrant immediate delivery. This means 
that if there is no result, immediate delivery should be performed. This could mean 
that a high FBS failure rate might also result in unnecessary operative intervention. 
As described in Chapter 6, we obtained a result with the use of SSL in 86% of cases 
where pH analysis failed. Assuming that in those cases operative delivery would have 
been performed because of no pH result, one might argue that the availability of an 
SSL has prevented operative delivery in those cases.
The goal of intra partum fetal monitoring is to prevent adverse neonatal outcome. 
The low prevalence of poor neonatal outcome is a common problem in evaluating 
tests for fetal well-being during labor. FBS is an important tool to exclude acidosis 
when the CTG is abnormal or, in the case of STAN monitoring, if the physician is 
uncertain of fetal well-being and additional information is required. As described 
in Chapter 6, the implementation of STAN in our institution did not result in 
an improvement in neonatal outcome. Observational studies from Sweden and 
Norway illustrated that with increasing STAN use over time, a low neonatal 
metabolic acidosis rate can be achieved (50, 51). In these countries, STAN was 
introduced many years earlier. As with all new medical technologies requiring user 
input, a significant learning curve exists (52). Since clinical success may be highly 
dependent on the skill of the clinician and observed effectiveness of the technology 
may improve as skills develop. Furthermore, the incidence of adverse events may 
decrease, improving the overall benefit risk relationship of the technique. The success 
of both FBS and STAN depends on correct interpretation of the CTG pattern and 
the appropriate intervention (or non-intervention), which makes them susceptible 
to human fallibility. Therefore, adequate organization with continuous monitoring, 
teaching and learning is needed.
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Implications for practice
In conclusion, the implications for practice include:
• FBS is very useful in clinical practice through excluding metabolic acidosis, 
thereby compensating the high false positive rate of an abnormal CTG.
• The use of Point of Care lactate can solve the high failure rate associated with 
FBS.
• Discrepancies between lactate and pH in FBS are common. As both parameters 
might reflect different aspects of a developing acidemia, combined testing is 
recommended.
• FBS can reduce the overall rate of assisted vaginal delivery and has the potential 
to reduce the CS rate.
• STAN is useful in clinical practice through providing more attention towards 
CTG interpretation, classification, as well as reducing FBS usage and metabolic 
acidosis at birth.
• A continuous focus on the quality of intrapartum surveillance, by prioritizing 
the 24/7 presence of experienced clinicians on the labor ward, as well as critical 
case discussions and continuous training is essential for this.
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Topics for future research
On the basis of this thesis, the following topics for further research are suggested:
• A randomized trial comparing CTG to CTG with FBS in order to determine if 
FBS is (cost) effective in preventing CS in case of suspected fetal distress during 
the first stage of labor and to what extent FBS affects perinatal outcome.
• A randomized trial comparing single testing (pH) to combined testing (pH and 
lactate) in FBS in order to determine which method is superior in preventing 
operative delivery and poor neonatal outcome.
• A prospective observational cohort study comparing our fetal monitoring 
protocol with those in other hospitals in order to investigate the value of 
FBS in addition to CTG and STAN. This may be a good alternative to the 
above mentioned RCT’s as one may question the feasibility and usefulness of 
randomized trials in complex settings as intrapartum fetal monitoring.
• Development of improved techniques for fetal monitoring, such as computerized 
analysis of fetal heart rate variability, automated interpretation of the CTG, and 
non-invasive analysis of the fetal ECG.
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Summary
Cardiotocography (CTG) - a simultaneous recording of the fetal heart rate and the 
contractions of the uterus - was introduced into obstetric practice during the 1970s 
and 1980s and is still a key component of fetal monitoring in modern obstetrics. 
In Chapter 1, a general introduction on this thesis is provided. It is explained that 
Intra-partum CTG is a useful screening test for hypoxia and subsequent acidosis, 
but requires supplementary tests to avoid unnecessary operative delivery. Fetal blood 
sampling (FBS) and ST-analysis of the fetal electrocardiogram (STAN) are two of 
the best known and accepted ones. FBS with pH or full blood gas analysis is used 
to identify those fetuses with suspected distress as actually being acidotic. FBS is 
invasive and associated with a high failure rate which can be solved by using lactate. 
Point of care (POC) lactate testing devices require only a tiny amount of blood and 
deliver fast results with a minimal failure rate. However, lactate measurements are 
not standardized and values vary with each device used. 
STAN is less invasive than FBS. Meta-analysis comparing STAN to CTG with or 
without FBS have confirmed a lower rate of metabolic acidosis, a reduction in the 
rate of FBS and a reduction in the overall rate of assisted vaginal delivery. There 
was no reduction in the rate of operative delivery for fetal distress, perinatal death, 
seizures and encephalopathy. It is unclear if STAN makes FBS redundant or not. 
In the Netherlands, a large practice variation exists in fetal surveillance during 
labor. Although all Dutch labor wards use CTG, in 23% of the hospitals, STAN 
is used to monitor fetal condition. In all but one hospital (98%), FBS facilities are 
available, but the frequency of FBS use varies between 3-15% of deliveries. It is 
suggested that this is mainly due to the variation in the indication to perform FBS. 
Evidence based guidelines on when to perform FBS are lacking. Furthermore, there 
is ongoing discussion on whether to use pH or lactate as a marker in FBS and there 
is uncertainty about the scalp lactate level at which to initiate intervention during 
labor. In this thesis, we have elaborated further on these challenges with the aim to 
guide best practice.
The quantification of the inter-and intra-observer agreement of non-reassuring 
intrapartum CTG patterns prior to FBS is presented in Chapter 2. Inter- and intra-
observer agreement was assessed by calculating weighted kappa values (Kw) and 
proportions of agreement (Pa). Nine observers assessed CTG patterns, which were 
formerly clinically classified as non-reassuring and indicative for FBS, according to 
the CTG guidelines of the International Federation of Gynecology and Obstetrics 
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modified for ST-analysis. The observers also proposed clinical management strategies 
with and without insight into clinical parameters. Inter-observer agreement on CTG 
classification and on clinical management were poor for most observer categories. 
Observers agreed best on abnormal CTG patterns (Pa range 0.28 – 0.36) and on the 
clinical management option ‘continue monitoring’ (Pa range 0.32 – 0.40). Intra-
observer agreement was fair to good for most observers (Kw 0.33 – 0.70). Insight into 
clinical parameters resulted in similar inter- and intra-observer agreement. From this 
study, it was concluded that the inter observer agreement on CTG patterns prior to 
FBS is poor and thus a relatively high chance that clinicians would disagree on the 
need to perform FBS. To ensure that FBS is as efficient as possible, the indication 
should be more strictly described in a well implemented guideline providing a clear 
association between the different CTG classifications and subsequent management.
In Chapter 3, it is described to what extent the fetal scalp blood lactate concentration 
during labor correlates with fetal scalp pH and base deficit, and metabolic acidosis at 
birth. In addition, lactate cut-off values to serve as indicators for either reassurance or 
immediate intervention are suggested. For this purpose, fetal scalp- and cord blood 
samples with acid-base and lactate values from 486 singleton pregnancies beyond 
34 weeks’ gestation were analyzed. Measurements were performed on a blood gas 
analyzer (RapidLab-860, Siemens Health Care Diagnostics). The relation between 
lactate, pH and base deficit (BD) in fetal scalp blood was tested by Spearman’s 
rho correlation coefficient. Lactate cut-off values indicating either reassuring fetal 
status or immediate intervention were estimated using percentile distribution and 
compared to pH and BD. Metabolic acidosis was defined as umbilical cord artery 
pH below 7.05 and base deficit (BD) calculated for the blood compartment above 12 
mmol/l. It was found that the fetal lactate values increased with evolving metabolic 
acidosis. The lactate concentration correlated with both pH (r= -0.50, p < 0.01) and 
BD (r= 0.48, p < 0.01). A lactate value < 5.4 mmol/l indicated reassuring fetal status, 
whereas a lactate ≥ 6.6 mmol/l indicated metabolic acidosis. Fetal lactate correlated 
better with either the absence or presence of metabolic acidosis at birth than did fetal 
pH and BD. It was concluded that in case of a non-reassuring CTG, the fetal scalp 
blood lactate value provided more accurate information on fetal acid-base status than 
pH and/or BD. As lactate analysis is easier, faster, and more often successful, fetal 
scalp blood lactate is an attractive alternative to full blood gas analysis in FBS.
The lactate cut-off values of 5,4 mmol/L and 6.6 mmol/l are absolute values and 
only valid with the Rapidlab-860 (RL), which is a large blood gas analyzer requiring 
a minimum sampling volume of 50 microliters. The requirement of at least 50 
microliters for blood gas analyzers results in high FBS failure rates. POC lactate 
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testing devices are attractive for their use in FBS because of the low sampling volume 
(0.7–5.0/L), rapid results (13–60 s) and low failure rates (1%–3%). However, due 
to lack of standardization, test characteristics and lactate cut-off values in FBS have 
to be determined for each measurement device. In Chapter 4, the evaluation of 
the performance of two POC lactate meters for intrapartum use is presented. The 
StatStrip Lactate (Nova Biomedical) and Lactate Pro (Arkray) were evaluated. To get 
an overall impression of performance of the StatStrip Lactate (SSL and Lactate Pro 
(LP), lactate concentrations were determined at three different levels according to the 
CLSI EP10 protocol. Total coefficients of variation (CV’s) were determined based on 
within-day and between-day variation. Analytical performance was evaluated further 
using cord artery and fetal scalp blood in a comparison study. Both POC meters 
were compared with our lactate reference method (RL) using fetal scalp and neonatal 
cord blood. Deming regression analysis was performed. The CV’s for SSL were lower 
than for LP. Consecutive lactate measurements in 37 fetal scalp and 122 cord blood 
samples revealed different test characteristics for the two POC devices, with SSL 
showing the closest correlation to RL. From this study, it was concluded that in 
comparison to LP, SSL showed the better analytical performance characteristics, 
with the lowest coefficients of variance, the closest correlation to and the highest 
agreement with our reference method.
We therefore chose to evaluate Statstrip lactate (SSL) for its use in FBS in the 
clinical setting in comparison to lactate (RLL) and pH (RLpH) by RapidLab. The 
outcome of this evaluation is presented in Chapter 5. For the purpose of this study 
we considered a SSL value ≤ 5.7 mmol/l indicative for reassuring fetal status and a 
SSL value ≥ 7.0 mmol/l representing acidemia.  These cut-off values were established 
by introducing the RL lactate cut-off values (5.4 and 6.6 mmol/L) into the formula: 
SSL = 1.13*RL - 0.39, which was generated from the findings described in Chapter 
4.  The discrepancy rates were studied using cross-tabulation. We obtained 323 FBS-
samples from 139 women. Parallel sampling of SSL and RLL/RLpH was performed 
in 247 samples. Outcome measures were the agreement and discrepancy rates between 
SSL, RLL and RLpH and the failure rate of all three methods. We constructed a 
Bland-Altman graph to assess the variability between the measurements across the 
range of values. SSL showed excellent agreement with RLL and poor agreement with 
RLpH. Failure rates for SSL, RLL and RLpH were 7%, 43% and 23% respectively. 
Using the cut-off values for reassurance and immediate delivery, the discrepancy 
rates between SSL and RLpH were 14% and 5% respectively. It was shown that 
with the use of the experimentally established cut-off values, SSL provides accurate 
information on fetal status in the vast majority of cases. As discrepancies between 
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lactate and pH are common and the cut-off values have not yet been evaluated and 
prospectively tested regarding intervention rates and neonatal outcome, we proposed 
combined testing of lactate (SSL) and pH in FBS.
To improve fetal monitoring in the Radboud University Medical Center in general 
and specially to reduce the high FBS failure rate of 20-30% we implemented two 
new procedures on our labor ward: STAN and POC lactate testing in FBS in parallel 
with pH according to a new clinical guideline on intrapartum fetal monitoring. In 
Chapter 6, the results of the two-year follow-up of these measures are presented. For 
this study, we compared to birth cohorts with singleton vertex deliveries ≥ 36 weeks. 
Cohort one ranged from 2010-2011, cohort two from 2014-2016. We assessed 
maternal and neonatal data including mode of delivery, birthweight, Apgarscore, 
FBS and cord blood acid-base values. Main outcome measures were FBS failure rate, 
operative deliver rates and metabolic acidosis at birth. The FBS failure rate decreased 
from 23 % to 2%. The percentage of labors in which FBS was used remained stable 
at 12%, while the number of samples per labor decreased from 2.3 to 1.6. In cases 
where FBS was performed, we found a significant decrease in ventouse delivery (from 
37 to 27%) and a significant increase in spontaneous vaginal delivery (from 37 to 
49%). The number of infants with low Apgar score and neonatal metabolic acidosis 
remained stable. From this study, it was concluded that the implementation of these 
two measures resulted in a tenfold decrease in FBS failure rate, fewer scalp samples 
per labor and a higher proportion of spontaneous vaginal deliveries with comparable 
perinatal outcome. 
The ideal method for fetal monitoring would be simple, noninvasive, and applicable 
for all women in labor, irrespective of gestational age. In Chapter 7, it is explained 
why neither FBS, nor STAN fulfill all of these demands but that their integrated use 
could be the way to move forward. From the findings in this thesis it is concluded that 
FBS is very useful in clinical practice through excluding metabolic acidosis, thereby 
compensating the high false positive rate of an abnormal CTG. The high failure rate 
associated with FBS can be solved with the use of Point of care lactate. Discrepancies 
between lactate and pH in FBS are common and as both parameters might reflect 
different aspects of a developing acidemia, combined testing is recommended. FBS 
can reduce the overall rate of assisted vaginal delivery and has the potential to reduce 
the cesarean section rate. STAN is useful in clinical practice through providing more 
attention towards CTG interpretation, classification and, in general, a reduction in 
FBS usage and neonatal metabolic acidosis. A continuous focus on the quality of 
intrapartum surveillance, by prioritizing the 24/7 presence of experienced clinicians 
on the labor ward, as well as critical case discussions and continuous training is 
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essential for this. Currently, there is intense debate as to whether both STAN and 
FBS have a place in contemporary obstetric practice, or whether their use should be 
discouraged and discontinued. The results of our studies can help to improve fetal 
monitoring in daily practice. Future studies regarding the efficacy of FBS and the 
development of improved (non-invasive) techniques of fetal monitoring are needed.
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Cardiotocografie (CTG) - een simultane registratie van het foetaal hartritme en de 
uteruscontracties- werd in de jaren ‘70 en ‘80 van de vorige eeuw geïntroduceerd in 
de klinische verloskunde praktijk en is nog steeds een de belangrijkste methoden voor 
foetale bewaking. Hoofdstuk 1 van dit proefschrift is een algemene introductie waarin 
wordt uitgelegd dat het intrapartum CTG weliswaar een goede screeningstest voor 
foetale hypoxie en daaropvolgende acidose is, maar dat aanvullende technieken nodig 
zijn om onnodige interventie tijdens de baring te voorkomen. Microbloedonderzoek 
(MBO) en ST-analyse van het foetale electrocardiogram (STAN) zijn de meest 
bekende en geaccepteerde technieken. Bij MBO wordt wat bloed uit de foetale 
(hoofd)huid afgenomen om hierin een pH of volledige bloedgasanalyse te verrichten. 
De techniek wordt gebruikt om bij afwijkende CTG-patronen na te gaan of de foetus 
in kwestie daadwerkelijk aan het verzuren is. MBO is invasief en geassocieerd met 
een grote mislukkingskans welke sterk kan worden gereduceerd door alleen lactaat 
te bepalen. Point of care (POC) lactaat meters hebben een zeer kleine hoeveelheid 
bloed nodig en leveren binnen een minuut resultaat met een minimale kans op 
een mislukte meting. De lactaatmeting is echter niet gestandaardiseerd en gemeten 
waarden variëren per apparaat. 
STAN is minder invasief dan MBO en maakt gebruik van veranderingen in het foetale 
ECG die zijn geassocieerd met hypoxie van het foetale hart. Om deze veranderingen 
in het ECG te meten is het spiraalelectrode op het voorliggend deel noodzakelijk. 
Diverse meta-analyses waarin STAN is vergeleken met CTG (met of zonder MBO) 
lieten een reductie zien in het aantal gevallen van neonatale metabole acidose, het 
aantal MBO’s en het aantal vaginale kunstverlossingen voor alle indicaties. Er werd 
geen reductie gezien in het aantal keizersneden, vaginale kunstverlossingen voor 
foetale nood, perinatale sterfte, convulsies en encefalopathie. Het is niet duidelijk of 
STAN het MBO overbodig maakt. 
In Nederland bestaat er een grote praktijkvariatie in de gebruikte methoden voor 
intrapartum foetale bewaking. Alle verloskundeafdelingen gebruiken CTG en in 23% 
van de ziekenhuizen wordt STAN gebruikt. In bijna alle ziekenhuizen zijn MBO-
faciliteiten beschikbaar, maar de frequentie waarin MBO verricht wordt varieert van 
3-15% van alle bevallingen. De variatie in indicatiestelling voor het MBO zou hier 
een oorzaak van kunnen zijn. Evidence-based richtlijnen over wanneer een MBO 
te verrichten ontbreken en er is discussie over welke parameter in het MBO moet 
heinis-layout.indd   138 08/02/2018   15:20
139
Summary & Samenvatting
C
ha
pt
er
 8
worden gebruikt. Ook is er onduidelijkheid over welke scalplactaat waarde kan 
dienen als afkapwaarde voor interventie. Deze vragen zijn in dit proefschrift verder 
uitgewerkt met als doel een leidraad te bieden voor de beroepspraktijk. 
In hoofdstuk 2 wordt de kwantificering van de inter- en intra-observer 
overeenstemming van CTG-patronen voorafgaand aan MBO gepresenteerd. Deze 
overeenstemming werd vastgesteld door middel van het berekenen van gewogen 
kappa waarden (kw) en proporties voor overeenstemming (Pa). Negen observanten 
beoordeelden CTG-patronen die voorheen in de kliniek waren geclassificeerd als 
niet geruststellend en indicatief voor MBO. De negen observanten deden ook 
beleidsvoorstellen met en zonder inzicht in de klinische parameters. De inter-observer 
overeenstemming over de CTG-classificatie en het klinisch beleid was in de meeste 
categorieën slecht. De meeste overeenstemming was er in de categorie abnormaal 
CTG (Pa range 0.28 – 0.36) en het beleidsvoorstel ‘continueer CTG’ (Pa range 0.32 
– 0.40). Inzicht in de klinische parameters resulteerde in een inter en intra observer 
overeenstemming van gelijke grootte. De conclusie van deze studie was dat de inter 
observer overeenstemming over CTG-patronen voorafgaand aan MBO slecht is en er 
daarmee een relatief grote kans bestaat dat clinici het niet eens zijn over de indicatie 
tot MBO. Om MBO zo efficiënt mogelijk te maken, is het nodig de indicatiestelling 
nauwkeuriger te omschrijven in een goed geïmplementeerde klinische richtlijn met 
een duidelijke associatie tussen de verschillende CTG-klassen en de daaruit volgende 
beleidsopties.
In hoofdstuk 3 wordt beschreven in welke mate de scalplactaatconcentratie tijdens 
de baring correleert met de scalp-pH en base deficit en metabole acidose bij de 
geboorte. Ook worden afkapwaarden voor lactaat voorgesteld die kunnen dienen als 
indicatoren voor geruststelling of onmiddellijke interventie. Voor dit doel werden 
foetale scalp- en navelstrengbloedmonsters met zuur-base- en lactaatwaarden van 
486 eenling zwangerschappen boven de 34 weken geanalyseerd. De metingen werden 
uitgevoerd met een bloedgasanalyse apparaat (RapidLab 860, Siemens Health Care 
Diagnostiscs). De relatie tussen lactaat, pH en base deficit (BD) in foetaal scalpbloed 
werd getoetst middels Spearman’s rho correlatiecoëfficiënt. Afkapwaarden voor lactaat 
indicatief voor geruststelling dan wel onmiddellijke interventie werden geschat door 
middel van percentielverdeling en vergeleken met de pH en de BD. Metabole acidose 
werd gedefinieerd als een pH beneden de 7.05 en een BD boven de 12 mmol/L in 
de navelstrengarterie. Er werd gevonden dat de scalp lactaatwaarden stegen bij een 
zich ontwikkelende metabole verzuring. De lactaatconcentratie correleerde zowel 
met de pH (r= -0.50, p < 0.01) als met de BD (r= 0.48, p < 0.01). Een lactaatwaarde 
< 5.4 mmol/L was indicatief voor een geruststellende foetale status, terwijl een 
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lactaatwaarde ≥ 6.6 mmol/L metabole acidose aangaf. Scalplactaat correleerde beter 
met zowel de aan- als afwezigheid van metabole acidose bij de geboorte dan de scalp-
pH of –BD. Er werd geconcludeerd dat in geval van een niet geruststellend CTG, 
de scalplactaatwaarde meer informatie verschaft over de foetale zuur-base status 
dan de pH en/of BD. Omdat de analyse van lactaat, gemakkelijker, sneller en vaker 
succesvol is, kan de lactaatbepaling een aantrekkelijk alternatief zijn voor de pH/
bloedgasanalyse in het MBO.
De lactaat afkapwaarden van 5,4 mmol/L en 6,6 mmol/L zijn absolute waarden en 
gelden alleen voor de Rapidlab-860 (RL), een groot bloedgas analyse apparaat welke 
minimaal 50 microliter nodig heeft voor analyse. Met name dit grote volume leidt 
tot een hoog mislukkingspercentage (tot 30%)van het MBO. POC-lactaat meters 
hebben een heel klein volume nodig (0.7–5.0u/L, leveren snel resultaat (13–60 s) 
met een zeer lage mislukkingspercentage (1%–3%).  Dit maakt POC lactaatmeters 
voor gebruik in MBO erg aantrekkelijk. De POC-lactaatmeting is echter niet 
gestandaardiseerd, wat maakt dat testkarakteristieken en afkapwaarden voor gebruik 
in het MBO voor ieder meetinstrument moeten worden vastgesteld.  In hoofdstuk 
4 wordt de evaluatie van twee POC lactaatmeters voor intrapartum gebruik 
gepresenteerd. De StatStrip Lactate (Nova Biomedical) en de Lactate Pro (Arkray) 
werden geëvalueerd en vergeleken met onze lactaat referentie methode (RL). Om een 
globale indruk te krijgen van de prestaties van de StatStrip Lactate (SSL en de Lactate 
Pro (LP) werd de lactaatconcentratie op drie verschillende niveaus gemeten volgens 
het CLSI EP10 protocol. Coëfficiënten van variatie (CV’s) warden bepaald op basis 
binnen en tussen daagse-variatie. De analytische prestaties van beide POC meters 
werden verder geëvalueerd met behulp van scalp- en navelstrengbloed monsters 
en vergeleken met de RL. Hiervoor werd Deming regressieanalyse uitgevoerd. De 
variantie coëfficiënten voor de Statstrip Lactate (SSL) waren lager dan die van de 
Lactate Pro (LP). Opeenvolgende metingen in 37 foetale scalp bloedmonsters 
toonde verschillende testkarakteristieken voor de twee POC meters. De conclusie 
van deze studie was dat in vergelijking met de LP, de SSL de beste analytische 
prestaties leverde met de laagste variantie coëfficiënten en de sterkste correlatie met 
de referentiemethode vertoonde.
We hebben er daarom voor gekozen om de SSL voor gebruik in het MBO te 
evalueren in de klinische setting in vergelijking met de lactaat (RLL) en pH (RLpH) 
meting door het RapidLab 860 bloedgasanalyse apparaat. De uitkomsten van dit 
onderzoek zijn beschreven in hoofdstuk 5. Voor deze studie zijn een SSL-waarde 
≤ 5.7 mmol/l beschouwd als indicatief voor een geruststellende foetale status en 
een SSL-waarde ≥ 7.0 mmol/l representatief voor acidose.  Deze afkapwaarden 
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zijn vastgesteld door de RL-lactaatwaarden (5.4 and 6.6 mmol/L) om te rekenen 
met de formule SSL = 1.13*RL - 0.39, afkomstig uit de bevindingen beschreven 
in hoofdstuk 4. Discrepanties tussen de verschillende metingen zijn bestudeerd 
middels kruistabellen. Er zijn 323 MBO-samples van 139 vrouwen verkregen. 
Parallelle analyse van SSL and RLL/RLpH werd uitgevoerd in 247 samples. De 
uitkomstmaten waren; de overeenstemming en discrepantie percentages tussen 
SSL, RLL and RLpH en het mislukkingspercentage van de drie methoden. Een 
Bland-Altman plot werd geconstrueerd om de variabiliteit van de metingen langs 
de range van de waarden te bepalen. De SSL toonde uitstekende overeenstemming 
met RLL en zeer matige overeenstemming met RLpH. De mislukkingspercentages 
voor SSL, RLL and RLpH waren respectievelijk 7%, 43% en 23%. Gebruikmakend 
van de afkapwaarden voor geruststelling en onmiddellijke beëindiging van de baring 
waren de discrepantie percentages tussen SSL en RLpH respectievelijk 14% en 
5%. Gebruikmakend van de experimentele afkapwaarden, verschafte de metingen 
op de SSL accurate informatie over de foetale status in de overgrote meerderheid 
van de gevallen. Aangezien discrepanties tussen lactaat en pH vaak voorkomen en 
de afkapwaarden nog niet prospectief getoetst zijn voor wat betreft interventies en 
neonatale uitkomst, wordt gecombineerd testen van lactaat (SSL) en pH voorgesteld. 
Hoofdstuk 6 beschrijft de tweejarige follow-up van een tweetal methoden die zijn 
geïmplementeerd op de verlosafdeling van het Radboudumc teneinde de foetale 
bewaking te verbeteren en met name het hoge MBO-mislukkingspercentage van 
20-30% terug te dringen. De twee methoden waren; STAN en POC-lactaatmeting 
met de SSL in combinatie met pH volgens een nieuwe richtlijn foetale bewaking. 
Voor deze studie zijn twee geboorte cohorten van eenling partus van 36 weken of 
meer met elkaar vergeleken. Cohort één bestond uit de tijdsperiode 2010-2011, 
cohort twee omvatte de jaren 2014-2016. Maternale en neonatale data, inclusief 
modus partus, geboortegewicht, Apgarscore, MBO en navelstrengwaarden werden 
verzameld. Primaire uitkomstmaten waren: het MBO-mislukkingspercentage, het 
aantal kunstverlossingen en het aantal gevallen van neonatale metabole acidose. 
Het percentage bevallingen waarin MBO werd verricht bleef stabiel op 12%, 
terwijl het aantal MBO’s per baring daalde van 2,3% naar 1,6%. Het MBO-
mislukkingspercentage daalde van 23% naar 2%. Bij de baringen waar MBO werd 
verricht was een significante daling te zien in het aantal kunstverlossingen (van 
37% naar 27%) en was er een significante stijging van het aantal spontane vaginale 
baringen (van 37% naar 49%). Het aantal kinderen met een lage Apgarscore en 
neonatale metabole acidose bleef stabiel. Vanuit de resultaten van deze studie werd 
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geconcludeerd dat de implementatie van deze twee maatregelen, geresulteerd hebben 
in een 10-voudige afname van het percentage mislukte MBO’s, minder MBO’s per 
baring en meer spontane vaginale baringen bij een vergelijkbare perinatale uitkomst.
De ideale methode voor foetale bewaking is simpel, non-invasief en zou geschikt 
moeten zijn voor alle vrouwen in partu, ongeacht de zwangerschapsduur. In hoofdstuk 
7, wordt uitgelegd waarom noch MBO, noch STAN aan deze criteria voldoen, maar 
dat een geïntegreerd gebruik van beide methoden een manier kan zijn om de kwaliteit 
van foetale bewaking te verbeteren. Vanuit de bevindingen in dit proefschrift wordt 
geconcludeerd dat MBO een nuttig instrument is om metabole acidose uit te sluiten 
om daarmee het hoge aantal fout-positieve waarnemingen voor foetale nood van 
een abnormaal CTG te compenseren. Het hoge mislukkingspercentage dat met 
MBO geassocieerd is kan worden teruggedrongen door POC lactaat te gebruiken. 
Discrepanties tussen lactaat en pH in het MBO komen veel voor en omdat beide 
parameters een weerspiegeling zouden kunnen zijn van verschillende aspecten van 
een zich ontwikkelende acidemie wordt gecombineerd testen aanbevolen. MBO kan 
het overall percentage vaginale kunstverlossingen reduceren en heeft de potentie om 
ook het keizersnede percentage omlaag te brengen. STAN is van nut in de klinische 
praktijk omdat het gebruik van deze techniek leidt tot meer aandacht voor CTG-
interpretatie, classificatie en over het algemeen minder MBO’s en minder neonatale 
metabole acidose. Hiervoor is een continue focus op de kwaliteit van intrapartum 
bewaking door de 24/7 beschikbaarheid van ervaren clinici op de verlosafdeling 
en kritische casusbesprekingen essentieel. Momenteel is er intens debat over de 
vraag of zowel STAN als MBO een plaats hebben in de moderne verlospraktijk of 
dat het gebruik van deze methoden moet worden ontmoedigd en afgeschaft. De 
resultaten van de studies in dit proefschrift kunnen helpen foetale bewaking in de 
dagelijkse praktijk te verbeteren. Meer onderzoek naar de effectiviteit van MBO 
en de ontwikkeling van verbeterde (non-invasieve) foetale bewakingstechnieken is 
hierbij nodig.
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Dankwoord
Na zeven jaar is het dan eindelijk zover, het boekje is af. Graag wil ik van de 
gelegenheid gebruikmaken om alle mensen te bedanken die direct of indirect een 
bijdrage hebben geleverd aan de totstandkoming van dit proefschrift. Zonder jullie 
hulp was 21 maart 2018 een hele gewone werkdag was geweest! 
Professor Vandenbussche, beste Frank. Dank voor de mogelijkheid die je me hebt 
geboden als verloskundige te kunnen promoveren. Onze samenwerking begon toen 
ik weliswaar een tweetal artikelen had gepubliceerd maar niet meer voornemens was 
om te gaan promoveren. Jij kwam met het idee om een gerandomiseerde studie op 
te zetten naar de effectiviteit van het MBO. Bewijs voor die effectiviteit was immers 
schaars en gedateerd. De Scalp-trial is er helaas nooit gekomen, maar het werken 
aan de opzet van deze studie heeft mede bijgedragen aan de totstandkoming van dit 
proefschrift. 
Doctor van Drongelen, beste Joris. Wie had gedacht dat het zo gaan toen ik jou als 
poortarts ging inwerken op de verloskamers van ziekenhuis Bernhoven te Veghel. Ik 
leerde je vliezen breken, schedelelectrodes plaatsen en episiotomieën hechten, want 
dat waren, zo was mij van hogerhand ingefluisterd, de belangrijkste vaardigheden 
die een poortarts onder de knie moest krijgen. Wat was het leuk om je later in het 
Radboud, als gynaecoloog in opleiding weer tegen te komen. Toen heb ik op mijn 
beurt veel van jou geleerd. In de patiëntenzorg, maar vooral op onderzoeksgebied. 
Wat een mazzel had ik dat jij ook nog epidemioloog bent. Je humor gaf me altijd 
weer de moed om door te gaan. Je hanteerde daarbij meer dan eens de uitspraak: 
“Komt goed, alleen niet vandaag”. 
Doctor van Dillen, beste Jeroen. Jij raakte ook pas in een later stadium betrokken 
bij dit hele gebeuren. Door een moeilijke tijd in mijn leven lag het onderzoek al 
een tijd stil. Jij hebt me gestimuleerd de draad weer op te pakken. Dankzij jouw 
enthousiasmerende begeleiding en bemoedigende mails zijn de laatste drie 
hoofstukken van dit proefschrift een feit. Bij het schrijven van de algemene discussie 
was er sprake van een langdurige uitdrijving, welke dankzij jouw begeleiding toch is 
geëindigd in een spontane bevalling.
Professor Lotgering, beste Fred. Halverwege mijn masteropleiding, kwam ik met het 
idee om onderzoek te doen naar lactaat in het MBO. Vrijwel direct kwam jij met een 
aantal publicaties op Pubmed aanzetten waar ik wat aan zou kunnen hebben. Later 
volgden zinvolle suggesties over hoe dit aan te pakken. In een van de eerste mails 
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aan mij schreef je: ‘dit is alleszins publiceerbaar en daar moet dan ook naar worden 
gestreefd’. Okay dacht ik, een kwestie van mijn masterthese in het Engels vertalen. 
Niets bleek minder waar. Wat was dat eerste artikel een kluif! Na de data op zo’n 
beetje alle mogelijke manieren bekeken te hebben, was ik soms de totale verzuring 
nabij toen wederom een versie rood van de feedback retour kwam. Toen ik mijn 
wanhoop op een bepaald moment met je deelde, stuurde je een bemoedigende mail 
terug die eindigde met: Volhardt! Kort daarna was het rond.
Professor Spaanderman, beste Marc. Samen met Fred heb je aan de wieg gestaan van 
dit proefschrift en kan ik stellen dat ik op wetenschappelijk gebied het meeste van 
jullie heb geleerd. Jij en Fred zaten soms niet op een lijn, wat weleens moeilijk voor 
mij was, maar jullie vulden elkaar ook goed aan. Jij wist bijvoorbeeld de dataset in 
SPSS aan de praat te krijgen en had veel ideeën over welke analyses erop los te laten. 
Ook met het schrijven zelf heb je me erg goed geholpen. Je zat nooit ruim in je tijd, 
maar als ik dan weer eens met een SPSS-uitdraai kwam aanzetten waar je wel wat in 
zag, noemde je dat gekscherend ‘Nobel prize winning stuff’ en nam je dan toch de 
tijd om verder te helpen. 
Dit proefschrift is kritisch beoordeeld en vervolgens goedgekeurd door de leden van 
de manuscriptcommissie waarvoor ik hen hartelijk wil danken. 
Doctor Wiberg, dear Nana. I have known your scientific work on fetal blood 
sampling and lactate for quite some time. Those papers helped me gain insight in 
the complex matter that fetal scalp blood sampling is. Maybe this is the reason why 
our encounter at the scientific meeting of the American Association for Clinical 
Chemistry (AACC) on Point of Care testing in Copenhagen was familiar somehow. 
You kindly invited me and Shannon to your home where we had a very pleasant stay. 
I hope your questions at my defense won’t be too hard to answer and I’m looking 
forward for you and Linda to meet my family and friends at the party afterwards.
Beste Jacqueline Klein Gunnewiek en Janine Oosting, wanneer je een lactaatmeter 
wilt beoordelen op bruikbaarheid in het MBO, is de kennis, kunde en het netwerk van 
een klinisch chemicus onontbeerlijk. Jacqueline, jij kwam destijds met het lumineuze 
idee om met de data van alle MBO’s en navelstrenggassen uit het lab onderzoek te 
gaan doen, wat de basis vormde voor hoofdstuk 3 en 4 van dit proefschrift. 
Beste Jacqueline Dinnissen, Gerald Dulos en Egbert Brouwer. Dankzij jullie hulp 
kwam de database op orde en is het klinische gedeelte van de studie op de verloskamer 
goed verlopen.
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Beste Liesbeth Scheepers, ook jij hebt een rol gespeeld bij het ontstaan van dit 
proefschrift, want ik had jou gekozen als mijn begeleider tijdens de masteropleiding. 
Door je vertrek naar Maastricht was dat helaas van korte duur en heeft Marc je rol 
overgenomen. In die korte tijd heb je toch heel wat van mijn verslagen en opdrachten 
van zinvolle feedback voorzien. Toen ik uiteindelijk mijn masterthese moest gaan 
schrijven en ik op een congres Yves Jacquemyn had horen spreken over scalplactaat, 
was je direct enthousiast en heb je me in contact gebracht met de juiste mensen. 
Dear Andrei Malic and Germano Ferrari from Nova Biomedical. Thank you for 
providing the lactate meters and strips. This enabled us to conduct two of the studies 
in this thesis. I’m also thankful for the invitation to the AACC scientific meeting in 
Copenhagen almost two years ago. This gave me renewed energy to complete my 
research. Also, many thanks for your proof reading, Andrei. It has improved the 
manuscript substantially.
Lieve Sarah, via Jeroen heb ik je leren kennen toen je als student geneeskunde 
invulling zocht voor je wetenschapsstage. Hoe tof is het dat de dataset die wij destijds 
hebben aangelegd hebben, heeft geresulteerd in maar liefst drie artikelen, namelijk 
hoofdstuk 2, 5 en 6 van dit proefschrift. Ik vond het heel leuk om je samen met 
Jeroen te mogen begeleiden en ben ik dankbaar dat jij, samen met mijn broer Nils, 
straks als paranimf aan mijn zijde staat. En als staan niet meer gaat met die dikke 
buik dan ga je gewoon zitten hoor! 
Lieve Marijke, dankzij jouw burgerlijke ongehoorzaamheid is het allemaal begonnen. 
Toen Ineke interesse toonde in de masteropleiding voor klinische verloskundigen en 
ik kort daarna volgde, besloot jij als leidinggevend verloskundige, ondanks dat er 
eigenlijk maar plek was voor één, dat wij allebei naar Rotterdam moesten gaan. Ook 
vond je het belangrijk dat ik tijd kreeg voor het onderzoek en heb je ervoor gezorgd 
dat ik daar wat tijd van de baas voor kreeg. 
Lieve Ineke, samen startten wij in 2006 met de masteropleiding voor klinische 
verloskundigen. Twee- en-een half jaar met de trein op en neer van Nijmegen naar 
Rotterdam, wat een leuke tijd was dat. Ik denk niet dat ik het zo leuk had gevonden 
wanneer ik in mijn eentje was gegaan en denk er vaak aan terug. We waren echt 
maatjes en hebben elkaar veel geholpen met de overdaad aan opdrachten die er soms 
was. Ook zijn we samen naar Zweden gegaan voor de buitenland stage en hebben 
veel opgestoken van hoe de verloskundige zorg daar is georganiseerd. De presentatie 
die we erover maakten werd daar goed ontvangen op de werkvloer. 
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Beste oud-collega verloskundigen, verpleegkundigen, gynaecologen (i.o) en alle 
andere collega’s die ik nog ken uit mijn tijd in het Radboud. Bedankt voor de prettige 
samenwerking. Ook in moeilijke tijden heb ik jullie steun mogen ervaren.
Beste Loes, Marije en andere medewerkers van het secretariaat verloskunde en 
gynaecologie. Bedankt voor alle logistieke hulp rondom de totstandkoming van 
dit proefschrift. Met name ook voor de goede organisatie van het symposium 
voorafgaand aan mijn verdediging.
Lieve broer Nils, ik ben erg blij dat je straks samen met Sarah aan mijn zijde staat 
tijdens de verdediging. Wie had dat ooit gedacht toen we jong waren. We hadden 
vaak mot, maar konden ook veel lachen. We hebben best veel meegemaakt samen. 
Het overlijden van mama hakte erin. Tijdens haar ziekte heb je veel voor haar gezorgd 
hebt wat zwaar voor je moet zijn geweest. Je was er ook voor mij toen ik het moeilijk 
had. Dank daarvoor. Door alle drukte van een gezin en werk, zien we elkaar te 
weinig vind ik. Zullen we daar maar eens verandering in aanbrengen? Te beginnen 
bij vandaag.
Lieve papa, je bent nu al 47 jaar mijn vader en ik realiseer me dat ik veel van jou in 
me heb. Het kritische opvliegende, maar ook de doortastendheid, diepgravend- en 
gedrevenheid. Deze eigenschappen hebben me gebracht tot waar ik nu ben. Als klein 
meisje al luisterde ik altijd met veel aandacht naar de verhalen over wat je als dokter 
had meegemaakt. De verhalen over psychiatrie en verloskunde in het bijzonder. 
Toen ik mijn interesse voor de verloskunde aan jou en mama kenbaar maakte was 
je zichtbaar opgetogen. Je zei: “verloskunde, dat past bij jou. Het is een vak wat je 
uitoefent met je hoofd, je handen en je hart”. Dat ben ik roerend met je eens. 
Lieve Boukje, je bent nu al weer 16 jaar mijn stiefmoeder, al vind ik dat een rare 
term. Dank voor de liefde en zorg die je ons geeft. Nu ik wat meer tijd heb hoop 
ik dat we elkaar wat vaker zullen gaan zien. Misschien moeten Shannon en ik jullie 
binnenkort maar eens een privélesje salsadansen komen geven. Onderzoek heeft 
immers uitgewezen dat dansen, in vergelijking met fitness, de beste manier is om 
veroudering van het brein tegen te gaan1.
Beste Bas, we zijn niet meer samen maar blijven altijd ouders van vier prachtige 
kinderen. Ik ben je dankbaar voor de mooie tijden die we samen hebben gekend en 
de keren dat je de kinderen hebt opgevangen als ik boven zat te schrijven.
1. Rehfeld K. et al. Dancing or Fitness Sport? The Effects of Two Training Programs on Hippocampal Plasticity and 
Balance Abilities in Healthy Seniors. Front Hum Neurosci. 2017 Jun 15;11:305.
heinis-layout.indd   150 08/02/2018   15:20
151
Addendum
Ad
de
nd
um
Meint, Cees, Loet en Simon, lieve kinderen van mij. Wat ben ik blij dat jullie in mijn 
leven zijn en wat is het leuk om jullie te zien opgroeien. Ik ben heel trots op jullie, 
want ik heb gezien dat jullie goed voor mij en anderen kunnen zorgen. Nu dit alles 
achter de rug is heb ik gelukkig meer tijd voor jullie. Het vaak gehoorde “Zit je nu 
alweer achter je laptop, mama” behoort definitief tot het verleden.
Lieve Cees en Mieke, wat was het fijn dat we tijdelijk bij jullie in huis konden wonen 
en wat hebben jullie ons goed geholpen om zaken goed op de rit te krijgen. 
Lieve Billy en Neeltje, dankzij jullie kan ik ook een beetje ervaren hoe het is om 
dochters te hebben. Ik vind het fijn om te zien dat jullie steeds meer vertrouwd met 
me raken. Ook geniet ik van jullie zangkunsten en ben ik heel blij dat jullie je vader 
weer aan het salsa dansen hebben gekregen. 
Lieve Shannon, allerliefste man van mij. Als jij er niet was geweest dan denk ik niet 
dat dit proefschrift ooit was afgekomen. Je was mijn eerste hulp bij Excel problemen, 
paniek en/of driftaanvallen. Als ik weer eens huilende opbelde omdat het niet lukte, 
dan zei je altijd heel kalm: “Ik moet om je lachen, je bent zo voorspelbaar. Altijd volg 
je hetzelfde patroon; je gaat huilen en dan is het de volgende dag af”. Je hebt steeds 
gelijk gekregen. Liefste, wat ik je verder nog te zeggen heb blijft tussen ons, maar 
wat ik hier wil uitspreken is dat ik hoop nog lang met jou door dit leven te kunnen 
dansen.
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Curriculum Vitae
Ayesha Maria Francisca Heinis werd op 8 maart 1971 in Amstelveen geboren.  Haar 
moeder beviel thuis -op de studentencampus Uilenstede - onder de hoede van haar 
huisarts.
Als peuter gaf zij al blijk van wetenschappelijke nieuwsgierigheid. Genesteld onder 
het bureau van haar studerende vader bracht zij uren door met het bekijken van 
atlassen anatomie en dermatologie.
Haar adolescentieperiode bracht zij door in de Achterhoek, bezocht het VWO aan 
het Ulenhofcollege te Doetinchem. Een duidelijk beeld van haar toekomst had zij op 
dat moment nog niet: misschien iets in de gezondheidszorg. Op naar de HBO-V aan 
de Hogeschool Enschede. Positieve verhalen van haar vader over de obstetrie hielpen 
haar bij de keuze voor verloskunde. Aan de Vroedvrouwenschool te Kerkrade volgde 
zij de opleiding tot verloskundige die zij cum laude afsloot.
Na een aantal jaren als verloskundige in de eerste lijn te hebben gewerkt, maakte zij de 
switch naar de klinische verloskunde, eerst in ziekenhuis Bernoven te Veghel en vanaf 
2006 in het Radboud UMC. Hier groeide haar wetenschappelijke belangstelling 
en zag zij het belang in van verdere professionalisering en inhoudelijke verdieping 
van haar beroep. Daartoe volgde zij aan de Hogeschool Rotterdam de opleiding 
tot Master Physician Assistant Klinisch Verloskundige, die zij cum laude afsloot. 
Inmiddels werkt zij als docent aan deze opleiding.
Uit haar vorige relatie heeft Ayesha vier zonen. Met haar nieuwe levenspartner 
beoefent zij met passie Zuid-Amerikaans dansen. Net als dansen vraagt verloskunde 
om een harmonieus samengaan van leiden en volgen. “It takes two to tango”.
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